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ABSTRACT
Adipose tissue serves two main functions in the body: (1) it is the body's primary energy depot;
and (2) it also serves as an important endocrine organ, producing and secreting various enzymes,
growth factors, cytokines, and hormones. Both of these functions require ample access to
circulating blood. Many aspects of angiogenesis during adipose tissue expansion remain poorly
understood. Adipocytes produce a large variety of molecules involved in angiogenesis, and
obesity is associated with elevated circulating levels of Vascular Endothelial Growh Factor
(VEGF). Our lab has previously shown that angiogenesis and adipogenesis are mutually
dependent via a VEGF receptor 2 (VEGFR2)-mediated mechanism. Since then several other
studies have reinforced a role for the VEGF-VEGFR system in energy metabolism. For example,
genetically obese mice treated with anti-VEGF antibody had lower fat pad weights, but the
VEGF receptor responsible for this observation is not known. There is also disagreement on the
cell type(s) responsible for fat tissue's angiogenic capability, with some studies supporting a
dominant role for adipocytes, while others attribute most of the angiogenic capacity to the
adipose tissue stromal cells (ASC).
This thesis project aimed to fill some of these gaps by examining the angiogenic capacity of
adipose tissue relative to other tissues, the effects of VEGFR-1 and R-2 blockade in mouse
models of adipogenesis and diet-induced obesity, the respective angiogenic capabilities of
adipocytes and ASC, and the possibility of harnessing the angiogenic potential of adipose tissue
for vascular tissue engineering. In addition, a physiologically-based mathematical model was
developed to simulate the regulatory effects of the leptin pathway on murine energy homeostasis.
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Chapter 1 : Introduction and Thesis Aims
Obesity as a medical problem
Obesity is a major worldwide public health problem, and its incidence is increasing at an
alarming rate. The prevalence of obese and overweight people in the United States has been
rising continuously since the late 1970's. Over 30% of the US population was obese and over
60% was overweight by year 20001. Far from being a solely cosmetic issue, obesity is associated
with a multitude of diseases, including type 2 diabetes mellitus, coronary heart disease,
endothelial dysfunction, respiratory complications, hypertension, osteoarthritis, and certain types
of cancers2-4. Recent studies have established that overweight and obese individuals have
significantly decreased life expectancies 5. Obesity is currently the second leading cause of death
in the US, accounting for an estimated 400,000 deaths per year6 . In year 2000, the direct (e.g.
doctor visits, medications, hospitalizations) and indirect (e.g. lost wages and productivity)
obesity-related health costs combined to a staggering $117 billion7 .
Obesity is notoriously obstinate: treatment directed towards long-term reduction in body weight
is seldom effective, with 90-95% of patients treated for obesity eventually regaining the weight
they lost8 . This is in part because energy homeostasis is under very rigid regulation by both
endocrine and nervous feedback systems8' 9. Studies in energy expenditure suggest that in each
person there may be a certain "stable" weight, and that any abrupt reduction or elevation of body
weight away from this stable weight is vigorously opposed by compensatory changes in energy
expenditurel0, 11. In addition, although obesity is generally considered to be caused by unhealthy
dietary habits and lack of exercise, it actually has a significant genetic component. The
heritability of obesity has been estimated to be between 50 and 90%12, which is roughly
equivalent to that of body height1 3.
The few currently approved drugs for treating obesity are limited by side effects and modest
efficacy, and are only effective while treatment remains active 14. The disappointing lack of
progress in the development of anti-obesity drugs prompted one author to remark that "since the
introduction of thyroid hormone to treat obesity in 1893, almost every drug that has been tried in
obese patients has led to undesirable outcomes that have resulted in their termination"". The
need for novel therapies to treat obesity is obvious.
Adipogenesis and angiogenesis
Adipose tissue serves two main functions in the body: (1) it is the body's primary energy depot;
and (2) it also serves as an important endocrine organ, producing and secreting various enzymes,
growth factors, cytokines, and hormones' 6. Both of these functions require ample access to the
blood stream. Indeed it has been shown that, on a per protoplasm basis, fat tissue is more richly
perfused by capillaries than skeletal muscles 17. During embryonic development, fat tissue and its
corresponding vasculature develop in close spatial and temporal synchrony; and in some
experimental animals, lean and obese fetuses can be distinguished by adipose tissue blood
vessels well before major differences in adipocyte size or number is observed' 8.
It has long been known that adipose tissue is highly angiogenic. Surgeons have been using
adipose tissue grafts to promote wound healing and to revascularize ischemic tissue for centuries,
a practice dating back to the early 17th century, when, after one of the many battles between the
Spaniards and the Dutch at the siege of Ostend, Dutch surgeons "sallied forth in strength... and
brought in great bags filled with human fat, esteemed the sovereignest remedy in the world for
wounds and disease" 19. To this day surgeons continue to use omental tissue transplants to
promote wound healing and revascularization 20. Adipocytes produce a large variety of molecules
involved in angiogenesis, including vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), leptin, and matrix metalloproteinases (MMPs) 21. Obesity is associated
with elevated serum VEGF in both mice (unpublished data by our lab) and humans 22. The
potential of the adipose tissue vasculature as a therapeutic target is demonstrated by two recent
studies showing that anti-angiogenic treatment significantly reduced body fat in several obese
mouse models without overt side effects23' 24
The goal of this project was to investigate the relationship between angiogenesis and
adipogenesis, and to apply such knowledge on two fronts: 1) identify potential therapeutic targets
for the treatment of obesity; and 2) harness the angiogenic potential of adipose tissue for vascular
tissue engineering.
Specific Aims
Hypothesis 1: Fat tissue has enhanced angiogenic capacity.
Specific Aim 1 a: Verify the angiogenic capability of fat tissue compared to other tissues.
Specific Aim lb: Examine the cell source responsible for fat tissue's angiogenic capacity.
Hypothesis 2: Engineered microvascular networks can support survival and function of
parenchymal cells
Specific Aim 2a: Utilize the cell source identified in Aim lb to produce stable engineered blood
vessels
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Specific Aim 2b: Incorporate parenchymal cells in tissue engineering constructs to determine
whether engineered vessels produced using our system could support the survival and function of
parenchymal cells.
Hypothesis 3: The VEGF-VEGFR system is involved in fat tissue angiogenesis
Specific Aim 3a: Examine the effect of pharmaceutical VEGFR1 and VEGFR2 inhibition on diet
induced obesity
Specific Aim 3b: Examine the effect of genetic disruption of the VEGFR1 pathway on diet
induced obesity
Specific Aim 3c: Characterize the metabolic defects in mice with genetic disruption of the
VEGFR1 pathway
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Chapter 2 : Angiogenic Capacity of Adipose Tissue
Portions of this chapter have been taken from:
Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain
RK. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo
adipogenesis. Circ Res. 2003 Oct 31; 93(9):e88-97.
Tam J*, Duda DG*, Perentes JY, Quadri RS, Fukumura D, Jain RK, Blockade of VEGFR2
and not VEGFR1 can limit diet-induced fat tissue expansion: Role of local versus bone-marrow
derived endothelial cells. Submitted. *Equal contributors.
Introduction
Adipose tissue serves two main functions in the body: (1) it is the body's primary energy depot;
and (2) it also serves as an important endocrine organ, producing and secreting various enzymes,
growth factors, cytokines, and hormones 16. Both of these functions require ample access to
circulating blood. Indeed it has been shown that, on a per protoplasm basis, fat tissue is more
richly perfused by capillaries than skeletal muscles' 7 . During embryonic development, fat tissue
and its corresponding vasculature develop in close spatial and temporal synchrony; and in some
experimental animals, lean and obese fetuses can be distinguished by adipose tissue blood
vessels well before major differences in adipocyte size or number is observed 18.
It has long been known that adipose tissue is highly angiogenic. Surgeons have been using
adipose tissue grafts to promote wound healing and to revascularize ischemic tissue for centuries,
a practice dating back to the early 17th century, when, after one of the many battles between the
Spaniards and the Dutch at the siege of Ostend, Dutch surgeons "sallied forth in strength... and
brought in great bags filled with human fat, esteemed the sovereignest remedy in the world for
wounds and disease" 9.
Vascular endothelial growth factor (VEGF) is believed to be responsible for most of adipose
tissue's angiogenic capacity25. VEGF is a master regulator of angiogenesis, in both physiologic
and pathologic conditions. VEGF binds to two tyrosine kinase receptors - VEGFR1 and
VEGFR2. VEGFR2 is responsible for the bulk of VEGF's angiogenic properties, including
promoting endothelial cell growth, survival, and migration, and increasing vascular
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permeability26. VEGFR1 was previously thought to be a non-signaling "decoy" receptor, but
recent studies have demonstrated its involvement in pathologic angiogenesis 27 and recruitment of
bone-marrow derived cells 28. Whereas VEGFR2 is mostly expressed by endothelial cells,
VEGFR1 is expressed by various cell types, including cells of the monocyte/macrophage
lineage 27, which have recently been recognized as a significant contributor to adipose tissue
composition and function2 9' 30
Many aspects of angiogenesis during adipose tissue expansion remain poorly understood. It is
generally accepted that adipose tissue is highly angiogenic, but whether adipose tissue is truly
more angiogenic than other tissues has never been demonstrated. VEGF is up-regulated during
adipogenesis 31, but there are conflicting reports regarding both local and systemic VEGF levels
during obesity 2 2 , 32-34. Our lab has previously shown that angiogenesis and adipogenesis are
mutually dependent via a VEGFR2-mediated mechanism35 . Since then several other studies have
reinforced a role for the VEGF-VEGFR system in fat tissue. Mice genetically deficient for
placental growth factor (PlGF, an agonist for VEGFR1) had lowered body weights during the
later stages of diet-induced obesity, but blocking P1GF pharmaceutically had no apparent effect36
Genetically obese and diabetic db/db mice treated with anti-VEGF antibody had lower
epididymal fat pad weights (there was no significant difference in total body weight within the 2
week treatment period), but the VEGF receptor responsible for this observation is not known3 7 .
There is also disagreement on the cell type(s) responsible for fat tissue's angiogenic capability,
with some studies supporting a dominant role for adipocytes 25' 38, while others attribute most of
the angiogenic capacity to the adipose tissue stromal cells (ASC) 39. The present study aimed to
fill some of these gaps by examining the angiogenic capacity of adipose tissue relative to other
tissues, the effects of VEGFR-1 and R-2 blockade in mouse models of adipogenesis and diet-
induced obesity, and the respective angiogenic capabilities of adipocytes and ASC.
Materials and Methods
Animal Models
All experimental use of animals has been approved by the Massachusetts General Hospital
Institutional Review Board Subcommittee on Research Animal Care. Animal welfare was
continuously monitored by the MGH veterinary staff.
Anesthesia
Animals were anesthetized during tail vein injection, dorsal skin chamber and cranial window
implantation, and during intravital microscopy, by intramuscular injection of ketamine/xylazine
(90mg/9mg per kg body wt). Effectiveness of anesthesia was monitored by respiration rate, toe
pinch, and muscular relaxation, and additional anesthetic was administered as necessary.
Dorsal skin chamber implantation
Dorsal skin chambers (DSC) were implanted in mice using a previously described procedure40
Prior to chamber implantation, the entire back of the animal was shaved and depilated, and
rinsed with ethanol. Two symmetrical titanium frames (weight 3.2 g), which were mirror images
of each other (Workshop, Department of Radiation Oncology, MGH) were implanted so as to
sandwich the extended double layer of skin. One layer of skin was removed in a circular area
approximately 15 mm in diameter, and the remaining layer, consisting of epidermis,
subcutaneous tissue, and striated muscle, was covered with a glass coverslip incorporated into
one of the frames. Following implantation of the transparent access chamber, animals were
allowed to recover from microsurgery and anesthesia for 48-h before cell/tissue implantation or
in vivo microscopy studies.
Intravital microscopy
Each mouse was positioned in a polycarbonate tube of approximately 25 mm of inner diameter
under anesthesia. Observations were made under trans- or epi-illumination employing long
working distance objectives and a microscope. Images from selected fields were recorded using
an intensified CCD camera and a video recorder, or a multi-photon laser scanning microscope.
Diets and body weight
Mice were fed either standard chow (Prolab Isopro RMH 3000, PMI Nutrition International,
LLC, Brentwood, MO), or a 60 kcal% fat diet (D12492, Research Diets, Inc. New Brunswick,
NJ). Mice were allowed ad libitum access to food, unless otherwise indicated. The body weight
of each mouse and the amount of food remaining in each cage were measured weekly. Food
spillage was not taken into account.
Reagents and Dosage
Rat anti-mouse monoclonal antibodies against VEGFR1 (MF1) and VEGFR2 (DC101) were
generous gifts from ImClone Systems Inc. (New York, NY). DC 101 was administered i.p. at
40mg/kg body weight every 3 days. MF1 was administered i.p. at 500 gpg/mouse every 2 days.
Cell lines and culture
The 3T3-F442A preadipocytes (a generous gift from Dr Bruce Spiegelman, Dana-Farber Cancer
Institute, Boston, Mass) and NIH 3T3 fibroblasts were maintained in Dulbecco's Minimum
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Essential Medium (DMEM, Gibco BRL), supplemented with 10% calf serum, glucose, L-
glutamine, penicillin, and streptomycin. A murine endothelial cell line (CRL-2279) was obtained
from ATCC (Manassas, Va) and cultured as recommended by the provider. For cell
identification in vivo, preadipocytes were transfected by the calcium phosphate method with the
green fluorescent protein (GFP) gene under the control of the EFla promoter41. For adipogenesis
inhibition, preadipocytes were transduced with a recombinant adenovirus encoding a PPARy-
dominant-negative (PPARy-DN) mutant receptor, or mock adenovirus, as previously described42.
Briefly, a multiplicity of infection of 103 for 90 minutes was used for transfection of confluent
(growth arrested) preadipocytes. The efficiency of the PPARy-DN construct was assessed
functionally, ie, by evaluating the cell differentiation. For in vivo experiments, transfected cells
were implanted 2 days after infection.
Extraction of adipose tissue cell fractions
Fat tissue was finely minced, then suspended in an equal volume of 2mg/ml collagenase (type 1,
Worthington Biochemical Corp., Lakewood, NJ), and incubated on a shaker at 370C for 1 hour.
The suspension was then passed through a 250 pm nylon mesh to remove undigested tissue. The
filtered suspension was centrifuged briefly, whereby adipocytes floated to the top of the
supernatant, while adipose stromal cells (ASCs) formed a pallet at the bottom of the centrifuge
tube. The cell fractions were collected separately and washed with PBS. Cells used for in vivo
imaging were implanted immediately after collection.
Results
Dependence of adipose tissue expansion on angiogenesis
In order to determine whether fat tissue expansion is dependent on angiogenesis, we investigated
the consequence of pharmacologically inhibiting VEGFR2 in several different mouse models.
VEGFR2 was chosen because it is a critical regulator of angiogenesis.
Effects of VEGFR2 inhibition on angiogenesis in implanted fat pads
The preadipocyte cell line 3T3-442A, which has been shown to differentiate into adipocytes
following in vivo implantation43, was implanted in mice baring dorsal skin chambers (DSC, see
methods section). In control animals, the implanted cells differentiated into fat-containing
adipocytes, accompanied by vigorous angiogenesis. In the animals treated with the monoclonal
anti-VEGFR2 antibody DC 101, not only was angiogenesis inhibited (as expected), adipogenesis
was surprisingly also inhibited, as demonstrated by the implanted cells' retention of the
fibroblast-like morphology that is characteristic of preadipocytes (Figure 2-1). Lack of
adipogenic differentiation was further confirmed by Northern blot analysis of the expression of
ap2 (a common marker for adipogenesis) 35.
In a parallel experiment, we investigated whether angiogenesis in this model was affected when
the implanted preadipocytes were prevented from differentiation into adipocytes. When
adipocyte differentiation was inhibited by a dominant negative PPARy gene construct, the
implanted preadipocytes did not differentiation, and, as expected, retained their fibroblastic
morphology (which is characteristic of preadipocytes) throughout the course of the experiment.
Surprisingly, the in vivo angiogenic response that follows the implantation of wild-type
preadipocytes was also almost completely suppressed when adipocyte differentiation was
inhibited35.
Since previous work in our lab has shown that neither VEGF nor VEGFR2 blockade has any
direct effects on adipocyte differentiation, we hypothesized that VEGFR2 signaling induces
endothelial cells to produce an adipogenesis-potentiating factor. We tested this hypothesis in
vitro by culturing preadipocytes using conditioned media from murine endothelial cells treated
with VEGF and VEGFR2 blocking antibody or an isotype control antibody. The conditioned
media from mEC cultured in the presence of VEGF increased preadipocyte survival/proliferation
and accelerated their differentiation. The blockade of VEGFR2 signaling almost completely
reversed the effects of VEGF. These results indicate that VEGFR2 signaling induces vascular
endothelial cells to secrete a paracrine factor that promotes adipogenesis, which at lease partly
explains the mechanism by which VEGFR2 blockade inhibits adipogenesis in vivo35
IgG DC101
1 week Adipocytes
Vasculature
4 Weeks Adipocytes
Vasculature
Figure 2-1. Representative images showing the effects of VEGFR2 blockage in implanted adipocytes and
accompanying vasculature. DC101: animals treated with the anti-VEGFR2 monoclonal antibody DC101. IgG:
control animals treated with isotype-matched IgG. Green: GFP-labeled 3T3-442A cells implanted in dorsal
chambers. Red: blood vessels visualized by intravenous injection of rhodamine-dextran. After 1 week of treatment,
there was no appreciable angiogenesis in either the DC 101 or the IgG treated groups, as the underlying vasculature
of the mouse skin, with a characteristic parallel distribution, is still clearly visible. Neither was there any appreciable
adipogenesis, as the implanted cells still maintained the fibroblast-like morphology that is characteristic of
preadipocytes. After 4 weeks of treatment, in the IgG group the implanted cells developed the rounded morphology
characteristic of mature adipocytes, as well as a fishnet-like new vascular network. This network consisted of new
vessels arising through angiogenesis, and is located on top of the underlying skin vasculature, such that the latter can
no longer be seen. In the DC 101 treated group the underlying vasculature of the mouse skin (with their characteristic
parallel orientation) is still clearly visible, indicating a lack of angiogenesis, which is the expected result of VEGFR2
blockage. Surprisingly, the implanted cells retained the fibroblast-like preadipocyte morphology. These results
indicate that when access to blood vessels is denied through the inhibition of angiogenesis, preadipocytes are unable
to differentiate into adipocytes.
Inhibition of VEGFR2 but not VEGFR1 delays diet-induced fat tissue expansion
The effects of blocking the VEGFR1 and VEGFR2 pathways on diet-induced obesity were
evaluated by feeding mice a high fat diet, and treating them with monoclonal anti-bodies against
VEGFR1 (MF1) or VEGFR2 (DC101). Male C57B1 mice, 9-11 weeks old, were fed a 60% fat
diet ad libitum, and given DC101, MF1, PBS, or no treatment, for over 8 weeks. We did not
observe overt signs of toxicity in any of the treatment groups. There was no significant
difference between the weight of mice treated with PBS and untreated mice throughout the
course of the experiment, therefore data from those two groups were pooled for subsequent
analyses (this pooled group will be referred to as HFD-control). Initially the administration of
DC101 had no effect on the body weight of high fat diet-treated mice. However, after the high
fat diet-treated mice gained about 25% weight, weight gain in DC101 treated animals slowed
considerably, such that there was no significant difference between the rate of weight gain in
DC 101 treated mice compared to mice kept on standard mouse chow (Figure 2-2A). This is
consistent with our previous finding that VEGF-VEGFR2 pathway is critical for both
angiogenesis and adipogenesis during de novo adipose tissue formation from preadipocyte.
During this period of lower body weight gain, the food intake in DC 101-treated group was
significantly smaller than in the control animals (Figure 2-2B). MF1 treatment had no
discernable affect on body weight over 8 weeks of treatment (Figure 2-2A). The effect of DC 101
was reversible, as the rate of weight gain resumed at a high pace after cessation of anti-VEGFR2
treatment, eventually reaching the weights of untreated controls (Figure 2-2C). Food intake was
similar during DC101 treatment and after cessation of treatment (2.35 vs 2.29 g/mouse/day,
p>0.7), even though there was significantly higher weight gain in the latter period, which
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suggests that although food intake in DC 101 treated mice was reduced compared to control mice,
it did not completely account for reduced body weight gain during DC 101 treatment.
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Figure 2-2. Effect of VEGFR1 and VEGFR2 blockade on body weight during DIO. Body weight gain relative to
weight at day 0 for mice given different diets and treatments. Male C57B6 mice, 10-12 weeks old at time 0, were
used for all groups. All diets and treatments began at day 0, at dosages and schedules as described in the Methods
section. DC101: high fat diet, DC101 treatment, black triangles. MFl: high fat diet, MF1 treatment, white squares.
HFD: high fat diet controls, no treatment (n = 4) or PBS treatment (n = 4), black circles. LFD: standard diet controls,
white circles. (B) Food intake (g/day/kg body weight) in the DC101 versus HFD-control, when the DC101 group
was gaining less weight (days 43-91). (C) DC101 treatment was discontinued from day 91 onward. About 2 weeks
after cessation of treatment, the rate of weight gain in the previously treated animals resumed at a higher pace, and
their body weights eventually caught up with untreated controls. Asterisks denote significant difference between
DC101 and HFD-control (two-sample t-test, P < 0.05). Data reported as mean ± sem.
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Enhanced angiogenic capacity in adipose tissue
To evaluate the angiogenic capacity of adipose tissue, the angiogenic response following in vivo
implantation of adipose tissue was monitored, and compared to implants of liver and kidney
tissues. Comparisons to other tissue types were made to determine whether the angiogenic
capacity commonly associated with adipose tissue amounts to any more than the normal hypoxic
response following the implantation of a non-perfused piece of tissue. The liver was chosen
because of its well-known regenerative ability, while the kidney provides another control tissue
for comparison.
Fat, liver, and kidney tissue from mice with constitutive GFP expression (driven by the EFla
promotor) were implanted in dorsal skinfold chambers, the subsequent angiogenic response was
monitored by intravital microscopy (IVM). Fat tissue induced a robust angiogenic response, with
numerous patent blood vessels visible throughout the implanted tissue by 2-3 weeks. In contrast,
the angiogenic response to liver and kidney tissue implants was much weaker - perfused blood
vessels were present only occasionally, primarily at the edge of the implants (Figure 2-3).
Results from this experiment showed that fat tissue is capable of inducing angiogenesis beyond
the extent caused merely by the normal hypoxic response following the implantation of a piece
of tissue.
Angiogenic potential of adipocytes compared to stromal vascular fraction offat tissue
Adipocytes were separated from stromal cells (ASC) by enzymatic digestion of fat tissue from
mice with constitutive GFP expression, and implanted separately into dorsal skinfold chambers
on mice that did not harbor GFP. Implanted adipocytes did not induce observable angiogenesis,
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and fluorescent cells were not observable after 2-3 weeks, presumably due to adipocyte cell
death. In contrast, ASC elicited a robust angiogenic response, with vascular tubes forming within
one week, and dense, perfused vascular networks formed by 2 weeks (Figure 2-4). Preadipocytes
in the ASC may have begun differentiating into adipocytes, as structures resembling lipid
droplets began appearing in the implanted cells within 2 weeks (Figure 2-5A). Many of the new
vessels are lined with GFP-positive cells, indicating that endothelial cells within the ASC are
significant contributors to the new blood vessels (Figure 2-5B). These results show that cells in
the stromal vascular faction of fat tissue are responsible for the bulk of fat tissue's angiogenic
capabilities, and that ASC directly contributed to the formation of new vessels, presumably by
supplying endothelial and/or peri-vascular mural cells.
Fat Kidn Liver
Figure 2-3. Representative images of the angiogenic response at 1,2, and 4 weeks following the implantation of
different tissue types. Fat (n=7), kidney (n=4), and liver (n=5) tissue pieces (-8 mm 3 each) from GFP-expressing
mice (green) were implanted in dorsal skinfold chambers, then monitored over 4 weeks. Blood vessels were
visualized by i.v. injection of tetramethylrhodamine labeled 200,000 MW dextran (red). Fat tissue induced a robust
angiogenic response: numerous perfused vessels were visible throughout the fat tissues by 2 weeks after
implantation. The angiogenic response was much weaker following the implantation of kidney and liver tissue.
Figure 2-4. Angiogenic response at time 0, 1, and 4 weeks following the implantation of adipocytes (n=3) or ASC
(n=3) from GFP-expressing mice (green). Blood vessels were visualized by i.v. injection of tetramethylrhodamine
labeled 200,000 MW dextran (red). ASC induced a robust angiogenic response, whereas no angiogenesis was
observed after implantation of fat cells alone.
Figure 2-5. (A) High power view of structures resembling lipid droplets in the implanted ASC after 2 weeks
(arrows). (B) GFP-expressing cells line new blood vessels (arrows) formed in response to the implantation of GFP-
expressing ASC.
Chapter 3 : Adipose Stromal Cells for Blood Vessel
Engineering
Data in this chapter have been collected in collaboration with Patrick Au.
Portions of this chapter have been taken from:
Au P, Tam J, Fukumura D, Jain RK. Bone marrow derived mesenchymal stem cells facilitate
engineering of long-lasting functional vasculature. Blood. 2008; 111(9): 4551-4558.
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Introduction
To date, almost all of the successfully engineered tissues/organs have relatively thin dimension
and/or avascular structures (e.g. skin44, cartilage45, bladder 46), where post-implantation
vascularization from the host is sufficient to meet the implant's demand for oxygen and nutrients.
Vascularization remains a critical obstacle impeding attempts to engineer thicker, metabolically
demanding organs such as the heart, brain and liver. The ability to produce long-lasting,
functional blood vessels would be a giant step forward for tissue engineering in order to repair
defective and/or damaged tissues/organs.
Our lab has developed a novel cell-based method to produce long-lasting, functional
microvessels 47. We hypothesized that peri-vascular mural cells, which have been largely
overlooked in tissue engineering attempts, play a crucial role in the survival and function of the
engineered vessels. We evaluated this hypothesis by comparing the process of vascular
development following the in vivo implantation of human umbilical-vein endothelial cells
(HUVECs), versus the vascular development that occurs after HUVECs were co-implanted with
10TI cells, a mesenchymal precursor cell line that is capable of differentiating into mural cells
through heterotypic interaction with endothelial cells. Blood vessels formed by HUVECs alone
showed minimal perfusion and lasted less than 60 days, whereas vessels formed by the co-
implantation of HUVECs and 10TI cells remained stable and functional more than one year
after the initial implantation.
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While the results from these studies were encouraging, this model cannot be immediately
adapted for human use because HUVECs and 10T 2 cells are not immunocompatible with
humans.
I have presented results in the last chapter showing that adipose stromal cells (ASC) are
responsible for the bulk of the angiogenic capability of adipose tissue. ASC is an attractive
alternative source for perivascular cells, due to the abundance, ease of harvest and low donor site
morbidity of fat tissue. A recent study also reported that ASC have protein expression and
functional characteristics that resemble pericytes48. The experiments described in this chapter
were aimed at determining whether ASC can replace 10T 2 cells in our vascular tissue
engineering system.
Materials and Methods
Animal Models
Animal maintenance, husbandry, and experimental procedures were as described in Chapter 2.
Cell culture
Discarded human fat tissue from liposuction procedures was obtained from Dr. Michael J.
Yaremchuk (The Boston Center, Boston, MA). Fat cells and adipose stromal cells (ASC) were
separated and collected as described in Chapter 2. Cells used for in vivo imaging were implanted
within 3 passages. Cells used for differentiation assays were cultured in the corresponding
differentiation medium (described below). C3H10T1/2 (10T1/2) (American Type Culture
Collection, Manassas, VA) were grown and maintained in Dulbecco's modified Eagle's medium
(DMEM) (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (FBS),
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penicillin (100 units/ml) and streptomycin (100 mg/ml) (Life Technologies, Inc). Human
umbilical cord vein endothelial cells (HUVECs) were obtained from Center of Excellence in
Vascular Biology, Brigham and Women's Hospital (Boston, MA) and maintained in Endothelial
Growth Medium (EGM, Cambrex).
Cranial Windows
Cranial windows (CWs) were implanted in mice following a previously published protocol 49, 50
The head of the animal was fixed by a stereotactic apparatus. The skin on top of the frontal and
parietal regions of the skull was cleaned with antimicrobial solution. A longitudinal incision of
the skin was made between the occiput and forehead. Then the skin was cut in a circular manner
on top of the skull, and the periosteum underneath was scraped off to the temporal crests. A 6-
mm circle was drawn over the frontal and parietal regions of the skull bilaterally. Using a high
speed air-turbine drill (CH4201S; Champion Dental Products, Placentia, CA) with a burr-tip 0.5
mm in diameter, a groove was made on the margin of the drawn circle. This groove was made
thinner by cautious and continuous drilling of the groove until the bone flap becomes loose. Cold
saline was applied during the drilling process to avoid thermal injury of the cortical regions.
Using a malis dissector, the bone flap was separated from the dura mater underneath. After
removal of the bone flap, the gelfoam was placed on the cutting edge and the dura mater was
continuously kept moist with physiological saline. A nick was made close to the sagittal sinus,
and iris microscissors were passed through the nick. The dura and arachnoid membranes were
cut completely from the surface of both hemispheres, avoiding any damage to the sagittal sinus.
The window was sealed with an 8-mm cover glass which was glued to the bone with
histocompatible cyanoacrylate glue.
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Preparation of the 3-D construct for tissue engineered blood vessels.
The engineered blood vessel model was prepared following a protocol previously established in
our lab 47' 5 1. 106 HUVECs and 2x105 ASC; 106 HUVECs and 2x105 10T1/2 cells; or 106
HUVECs alone were suspended in 1 ml solution of rat-tail type 1 collagen (1.5 mg/ml) (BD
Biosciences, Bedford, MA) and human plasma fibronectin (90 mg/ml) (Sigma) in 25 mM Hepes
(Sigma) buffered EGM medium at 40C. pH was adjusted to 7.4 with IN NaOH (Fisher Science,
NJ). The cell suspension was pipetted into 12 well plates (Falcon) and warmed to 37C for 30
min to allow polymerization of collagen. Each solidified gel construct was covered by 1 ml of
warmed EGM medium. After 1 day culture in 5% C02, a skin puncher was applied to create
circular disk-shape pieces of the construct (4-mm diameter). The circular piece of collagen gel
was then implanted into a cranial window of a severe combined immunodeficient (SCID) mouse.
The in vivo fate of the fluorescent protein-labeled endothelial cells was tracked by intravital
imaging with multiphoton laser scanning microscopy at various time points 52. Image was taken
with 20x/0.50 NA water objective.
Differentiation assays
The ability of pluripotent cells to differentiate along different lineages was tested by culturing
cells with adipogenic and osteogenic differentiation media. Adipogenic differentiation media
consisted of Dulbecco's Modified Eagle's Medium (DMEM), 10% fetal bovine serum (FBS),
0.5mM 3-Isobutyl-1-methylxanthine, 1 uM dexamethasone, 10 uM insulin, 200 uM
indomethacin, and 1% penicillin/streptomycin (pen/strep). Osteogenic differentiation media
consisted of DMEM, 10% FBS, 0.1 jtM 0.1 uM dexamethasone, 50 uM ascorbate-2-
phosphate, 10 mM b-glycerophosphate, 1% pen/strep. All cells were cultured in a humidified
incubator, at 37C and 5% CO2. After 4-6 weeks in culture, aidpogenic differentiation was
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confirmed by oil-red-O staining, while osteogenic differentiation was confirmed by alkaline
phosphatase staining.
Oil Red 0 staining protocol
Oil Red O stock solution was prepared by dissolving 0.03g of Oil Red O dye (Sigma-Aldrich, St.
Louis, MO) in 10 ml of 2-propanol. Undissolved solids were filtered out. Immediately prior to
use, a working Oil Red O stain was prepared by mixing 820 jpL of Oil Red O stock solution with
680 jpL of dH20. Cells were fixed in 4% paraformaldehyde at room temperature for 30 minutes,
then washed with water. The working stain was applied to the fixed cells and incubated at room
temperature for 20 min. Afterwards the cells were washed with water, allowed to air dry, then
counterstained with hematoxylin.
Alkaline phosphatase staining protocol
Alkaline phosphatase staining was performed using the Vector Red Alkaline Phosphatase
Substrate Kit I (Vector Laboratories), following the manufacturer's protocol. Briefly, fixed cells
were incubated in the Vector Red substrate working solution at room temperature for 30 minutes
in the dark. The working solution was then removed, and the cells were incubated in 100%
ethanol for 5 minutes. The cells were then mounted in VECTASHIELD mounting medium with
DAPI (Vector Laboratories).
Results
Stromal Vascular Fraction cells isolated from human fat tissue are multipotent
ASC were isolated from human fat tissue by enzymatic digestion and their multipotency was
tested by culturing with adipogenic and osteogenic differentiation media. After 4-6 weeks in
culture, adipogenic differentiation was confirmed by oil-red-O staining (Figure 3-1A), and
osteogenic differentiation was confirmed by alkaline phosphatase staining (Figure 3-1B). This
shows that ASC are able to differentiate along different specific lineages.
Figure 3-1. ASC from fat tissue are multipotent. (A) Adipogenic differentiation in ASC cultured in adipogenic
media was confirmed by oil-red-O staining (red), and counter-stained with hematoxylin (blue). (B) Osteogenic
differentiation in ASC cultured in osteogenic media was confirmed by alkaline phosphatase staining (red). Nuclei
were stained by DAPI (blue). ASC cultured in non-differentiating medium were used as negative controls (not
shown).
Ability of multipotent ASC to sustain engineered blood vessels
Multipotent ASC isolated from human adipose tissue were co-implanted with GFP-labeled
human umbilical vein endothelial cells (HUVECs) in collagen gels into cranial windows,
following a protocol previously established in our lab47. Blood vessels formed in the implants
were monitored regularly by intravital microscopy. Gel implants with HUVECs alone, and those
with HUVECs and 10T1/2 cells, were used as negative and positive controls, respectively. The
implanted HUVECs formed tubular structures within a few days after implantation in all three
cases. However, the tubular structures formed by HUVECs alone never became perfused, and all
the GFP-labeled HUVECs disappeared within 2 months (Figure 3-2A). On the other hand, the
HUVECs+ASC and HUVECs+10T1/2 constructs formed perfused blood vessel networks within
2 weeks after implantation (Figure 3-2A). The vessels in the HUVECs+ASC construct remained
patent for 2 months, but by the 3 month they began to regress (Figure 3-2A), and eventually they
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too disappeared. In contrast, vessels in HUVECs+I OT1/2 constructs typically remain stable and
functional for over a year47
In a parallel experiment, we investigated whether human bone marrow-derived mesenchymal
stem cells (hMSC) could be a suitable replacement for 10T1/2 cells. hMSC were able to stabilize
HUVECs to form blood vessels that remained patent and functional for more than 4 months in
vivo (Figure 3-2B)53. Results from this experiment show that while multipotent ASC from human
fat tissue are able to stabilize HUVECs to form patent engineered blood vessels for a time, this
effect is transient, and ASC may not be an ideal candidate cell source for replacing 10T1/2 cells
in our tissue engineering system. One potential reason for this is the fact that ASC have a
tendency to accumulate lipid (Figure 2-5A), and has been shown to spontaneously differentiate
into adipocytes in vivo54 , 55. Our tissue engineering system relies on the ability of mesenchymal
stem cells to differentiate into perivascular mural cells, which will in turn stabilize the
endothelial cells. The tendency of ASC to differentiate into adipocytes may undermine this
ability.
Given the unique advantages of ASC as a cell source for tissue engineering (ease of harvest,
minimal donor site morbidity), it may be worthwhile to investigate whether inhibiting the
differentiation of these cells into adipocytes, e.g. by using dominant negative gene constructs42,
makes them more suitable for tissue engineering applications.
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Figure 3-2. Tissue engineering of blood vessels in mice. Tissue constructs were produced and implanted into mice
baring cranial windows, as previously described47 . HUVECs labeled by GFP protein (green), functional blood
vessels visualized by rhodamine-dextran (red). (A) Consistent with our previous experience, implants with HUVECs
alone formed cord-like structures but were never perfused, and by 2 weeks post-implantation most of the green cells
had disappeared. When HUVECs were combined with multi-potent ASC, functional blood vessels were formed by 2
weeks post-implantation. These engineered blood vessels persisted for about 2 months, but most of them receded by
the 3 rd month. The period of stabilization provided by ASC is substantially less than 10T1/2 cells 47 or bone marrow-
derived mesenchymal stem cells53 . (B) Vessels formed by combining HUVECs and bone marrow-derived
mesenchymal stem cells remained patent more than 130 days after implantation53.
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Chapter 4 : Dynamic measurement of hepatocyte function by
two-photon microscopy
Data in this chapter have been collected in collaboration with Patrick Au.
Portions of this chapter have been taken from:
Au P*, Tam J", Kwok J, Fukumura D, Jain RK. Dynamic measurement of hepatic tissue
function by multiphoton microscopy. In preparation. *Equal contributors.
Introduction
Tissue assemblies greater than 100-200 micrometers (the limit of oxygen diffusion) cannot
survive for long without a perfused vascular bed to supply nutrients and to remove waste
products and metabolic intermediates 56. Besides their crucial role in providing oxygen and
nutrients, there is also a growing body of evidence showing that vascular networks play an
integral role in the development, organization, and function of a wide range of tissue types.
Blood vessel endothelium has been shown to play requisite roles in early liver57 and pancreas5 8
development, and liver regeneration following partial hepatectomy is dependent on
angiogenesis 59. Soluble factors secreted by endothelial cells stimulate neural stem cell self-
renewal and neuron production 60. Co-culture of cardiac myocytes and endothelial cells reduced
cardiac myocyte apoptosis and necrosis, and promoted cardiac myocyte reorganization and
function (synchronized contraction and connexin expression) 61. These examples suggest that a
long-lasting, functional vascular network will be required not only for adequate perfusion of the
tissue, but also for the proper cellular organization, development, and function of any
regenerating and/or engineered solid tissue construct.
Our laboratory has previously established a method for producing long-lasting functional
microvascular networks47 51, 53, 62 . In order to determine if microvascular networks produced by
this method could be used to support parenchymal cells, we investigated the possibility of adding
parenchymal cells to our tissue engineering constructs, and monitoring the survival and function
of the parenchymal cells following in vivo implantation. After studying the literature and some
preliminary experiments, we decided to use hepatocytes as the parenchymal cell type. However
one major obstacle had to be overcome before we could include hepatocytes in our system -
currently there is no established method to assess the functional status of in vivo engineered liver
tissues in real-time without extraction of the tissues. The most common way to assess hepatocyte
phenotype is to measure the production of characteristic proteins such as albumin and urea.
However, protein synthesis by engineered tissues is difficult to measure reliably in vivo, due to
the confounding effects of host production. To circumvent this problem, investigators often have
to resort to either extracting and destroying the engineered tissue after some time in vivo to
evaluate the mRNA or protein expression of characteristic markers, or performing hepatectomy
in animals prior to implantation of liver constructs, resulting in high mortality rates63. Other
methods focus on functional characteristics such as cytochrome P450 and glucuronidation
activities 64. However most of these methods were developed for cells in culture, requiring
analysis of conditioned media or cell lysates. To apply these methods in engineered liver tissue
implants again necessitates the extraction of the implants. This common requirement for
extraction of tissue implants restricts the experiment to only one measurable time point, and thus
severely limits the ability to evaluate the long-term in vivo viability and function of engineered
liver tissues.
To overcome this limitation, we have developed a novel imaging technique for measuring the
metabolic function of engineered liver tissues. We utilized multi-photon laser scanning
microscopy to interrogate, in real-time, the cytochrome P450 function of engineered liver tissues.
This method is non-invasive and does not require the extraction of tissues, thus it can potentially
be used for the long-term continuous monitoring of implanted liver tissue constructs.
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Material and Method
Materials
3-cyano-7-ethoxycoumarin (CEC) and 3-cyano-7-hydroxycoumarin (CHC) were purchased
from Invitrogen (Carlsbad, CA). CEC and CHC were dissolved in DMSO (Sigma, St. Louis,
MO) to a concentration of 30mM stock solution, stored at -200 C, and protected from light until
use.
Hepatocyte isolation and culture
Hepatocyte isolation was performed following a previously published protocol 65, with minor
adjustments. Neonatal (1-3 days old) mice were sacrificed by decapitation. The livers were
quickly removed, minced, then digested in 0.3% collagenase (type 2, Worthington Biochemical
Corp., Lakewood, NJ) for 30 minutes at 370C on a shaker. The cells were than passed through a
cell strainer (70 gm, BD Falcon, Bedford, MA), and washed twice by centrifugation. The cells
were then plated onto collagen 1 coated cell culture plates (BD BioCoat, BD Labware, Bedford,
MA), and cultured in Dulbecco's Modified Eagle Medium with high glucose, 10% fetal bovine
serum, 0.5 U/mL insulin, 7 ng/mL glucagons, 7.5 [lg/mL hydrocortisone, and 1% penicillin-
streptomycin66
Spectroscopic evaluation of CEC and CHC
The emission spectra of CEC and CHC were measured with a fluorescence spectrometer (Ocean
Optics, Dunedin FL). For the excitation spectra, the fluorescence emission was recorded and
averaged for 5s by a computer-controlled photon counter (Stanford Research Systems, Model
SR400). The excitation wavelength was tuned from 720 to 990nm with 20 nm resolution and the
power of the incident bean was kept constant with the means of a power meter. Two-photon
excitation of the dyes was confirmed by intensity test in order to demonstrate the power-squared
dependence of the fluorescence. The integrated fluorescence was measured at various excitation
intensities by a photon counter. The results were then plotted on a log-log scale and fit to a line.
The slope of the trend line yielded the power-dependence exponent.
Functional evaluation of hepatocytes grown in monolayer and in three-dimension in vitro
Neonatal hepatocytes were cultured on Type I collagen coated dish (BD Biosciece). In
experiments with induction of cytochrome P450, 30M of P-Napthoflavone was exposed to the
cells for 72 hours. On the day of experiment, the media were changed and replaced with DMEM
containing 30M of CEC. Cytochrome P450 activity was measured by submerging a 20x
objective (Zeiss Aeroplane) into the media. The cells were maintained at 37'C at all time by
placing the cell culture dish on a heating pad. CHC in the media was two-photon excited at 810
nm wavelength and emission was filtered through a 470nm/40 filter set. The fluorescence
emission was detected by a photomultiplier tube (Hamamatsu, Hamamatsu City, Japan) that was
fed to a gated photon counter (SR400, Stanford Research Systems, Sunnyvale, CA). The
concentration of CHC in the medium was determined by comparing the photon count to a
standard curve of CHC prepared in DMEM.
To grow hepatocytes in three-dimensional culture, neonatal hepatocytes were suspended in a
fibronectin/type I collage matrix as previously described 47' 53. Briefly, 300,000 hepatocytes were
suspended in 1 ml solution of rat-tail type 1 collagen (1.5 mg/ml) (BD Biosciences, Bedford, MA)
and human plasma fibronectin (90 pg/ml) (Sigma) in 25 mM Hepes (Sigma) buffered DMEM
medium at 40C. pH was adjusted to 7.4 by using IN NaOH (Fisher Science, NJ). The cell
suspension was pipetted into a single well of a 12 well plates and warmed to 37'C for 30 min to
allow polymerization of collagen. Once the collagen gel had solidifed, one ml of warmed
DMEM medium was added into the well and the cell culture plate was then placed in an
incubator maintained at 37'C and 5% CO 2. After 4 days in culture, the hepatocytes-laded gel was
exposed to 30pM of 3-Napthoflavone for 3 days to induced expression of P4501A2. A skin
puncher (4-mm diameter) was then applied to the collagen gel construct to excise a circular piece.
CytochromP450 activity was measured directly on the excised piece of hepatocytes-lade gel
using technique similarly to that of the hepatocyte monolayer. 30pM of CEC in DMEM was
applied to the collagen gel and a 20x water immersion objective piece was then lowered to make
contact with it. The collagen gel was imaged at various timepoints and flourescence intensity
was quantified.
Gene expression analysis
Gene expression was measured by real-time quantitative PCR (qRT-PCR). Total RNA was
isolated from neonatal hepatocytes using the RNeasy Mini Kit (Qiagen, Valencia, CA). Quantity
and purity of RNA were determined by ultraviolet absorbance at 260 and 280 nm. cDNA was
synthesized using TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City,
CA). qRT-PCR was performed using the 7300 Real-Time PCR System and Power SYBR Green
PCR Master Mix (Applied Biosystems). Primers were designed using Primer Express (Applied
Biosystems) or Primer3 (Whitehead Institute, Cambridge, MA), and purchased from Integrated
DNA Technologies (Coralville, IA). Primer sequences are listed in Table 4-1. Primer specificity
for each gene of interest was confirmed by comparison to known sequences in the BLAST
database (National Center for Biotechnology Information). Primer efficiency was validated using
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standard curves generated from 10-fold dilutions of mouse liver cDNA. Samples were analyzed
in triplicates, and the gene expression level for each sample was normalized to the corresponding
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) expression level, to control for loading
differences. Negative controls were performed for each sample using non-reverse-transcribed
RNA.
Table 4-1. Primer sequences for qRT-PCR
Gene Forward Primer (5'-3') Reverse Primer (5'-3')
CYP1Al CCACCTGCTGAGGCTAAACAG TGCCCCCCACATGCA
CYP1A2 CTGTCCAGGAGCACTACCAAGA TGAACAGGGCACTTGTGATGTC
GAPDH AAGAAGGTGGTGAAGCAGGCA TGCTGTTGAAGTCGCAGGAGA
CYPlA1, cytochrome P450, family 1, subfamily a, polypeptide 1;CYP1A2, cytochrome P450, family 1, subfamily a,
polypeptide 2; GAPDH, glyceraldehydes-3-phosphate dehydrogenase
Results
Spectroscopic property of CEC and CHC
We investigated the spectroscopic property of 3-cyano-ethoxycoumarin (CEC) and 3-cyan-
hydroxycoumarin (CHC) 67 . The dealkylation reaction of CEC to CHC is mediated by
cytochrome P450 1A2 in the endoplasmic reticulum of a hepatocyte68 (Figure 4-1A). We first
measured the emission spectra of CEC and CHC. The de-ethylation reaction yields a blue
fluorescent product with a maximum emission at 450nm, while the maximum emission of the
substrate, CEC, is at 430nm (Figure 4-1B). Next, we determined whether CEC and CHC could
be excited by 2-photon using near-infrared laser. Knowledge of the 2-photon excitation cross-
section spectra allows for a better signal to noise ratio and minimizes the potential for photo-
damage. The fluorescence signal was measured as the excitation wavelength was tuned from 720
to 990nm with 20 nm resolution (Figure 4-1C). The 2-photon excitation peak was 740 nm and
810 nm for CEC and CHC, respectively. This result in is in accordance with the expectation that
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the 2-photon excitation peak should be approximately doubled and slightly blue-shifted relative
to that of the single-photon excitation peak. We found that at 810nm, CHC was maximally
excited with minimal excitation of CEC. We decided to use this excitation wavelength for
subsequent in vitro and in vivo measurements.
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Figure 4-1. (A) Chemical structures of 3-cyano-7-ethoxycoumarin (CEC) and 3-cyano-7-hydroxycoumarin (CHC).
Cytochrome P4501A2 mediates the dealkylation of CEC into CHC. (B) Plot of fluorescent intensity versus emission
wavelength of CEC and CHC. CEC was dissolved in PBS at a concentration of 30pM and excited at 740nm. CHC
was dissolved in PBS at 500nM and excited at 810nm. (C) Plot of photon count versus excitation wavelength of
CEC and CHC tunes from 710 to 990nm.
Next, we tested whether we could quantitatively measure the amount of CHC (product) in the
presence or absence of CEC (substrate). We measured the fluorescence intensity of a range of
concentration of CHC at 810 nm excitation wavelength with 470/40nm filter set. We found that
the presence of the substrate had minimal effect on the measured fluorescence intensity when
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concentration of CHC in solution was above 10nM. We also determined that CHC concentration
ranging from 1 to 500nM was linearly related to the fluorescence intensity (Figure 4-2A). This
provides a simple means to quantify an unknown concentration of CHC by measuring its
fluorescent intensity. Finally, we investigated the dependence of fluorescence signal on incident
power. At 805nm excitation wavelength, the slope in the logarithmic plot of fluorescence versus
power was 1.8 (Figure 4-2B). We note that this is a departure from perfect power-squared
dependence. This suggests that in addition to two-photon events, there is some excitation of the
molecules by single photon.
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Figure 4-2. (A) Standard curve of photon count versus CHC concentration in the presence or absence of 30M of
CEC. (B) Logarithmic plot of photon count versus the incident intensity at 810nm excitation wavelengths for CHC.
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In vitro measurement ofP450 activity in neonatal hepatocytes
Next, we tested the conversion of CEC to CHC by cytochrome P450 in an in vitro culture of
neonatal hepatocytes. It is well known that the neonatal livers have reduced hepatic function and
activity69. Thus, we added a commonly used inducer of the cytochrome P450 1Al and 1A2
isoforms, 3-napthoflavone, to the culture medium for 72 hours. As expected, we observed an
induction of CYPlAl and CYP1A2 in the neonatal hepatocytes treated with P-napthoflavone:
real-time quantitative PCR showed increases of over 400 and 120 fold in the transcript levels of
CYPlAl and CYP1A2, respectively (Figure 4-3).
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Figure 4-3. Quantitative real-time PCR of neonatal hepatocytes treated with 30nM of f-napthoflavone or DMSO as
control. GAPDH was used to normalize expression level of cytochrome P450 1Al and 1A2.
To test for cytochrome P450 activity, we added 30 pM of CEC to a monolayer of hepatocytes and
measured the fluorescence intensity of the supernatant over time. In neonatal hepatocytes
without inducer treatment, no increase in the photon count was detected in the supernatant for
over 90 minutes (Figure 4-4). In contrast, hepatocytes that were stimulated with P-napthoflavone
showed a steady increase in the photon count consistent with the conversion of CEC into CHC
(Figure 4-4). To determine the specificity of the reaction, we added a-napthoflavone, a specific
inhibitor of the cytochrome P450 1A2 isoform, to the medium. With the addition of a-
napthoflavone, no further increase in the photon count was detected, suggesting a complete
inhibition of CHC production (Figure 4-4).
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Next, we evaluated CHC production in hepatocytes grown in three-dimensional culture.
Neonatal hepatocytes were suspended in type I collagen matrix and cultured for 72 hours with 3-
napthoflavone in the medium. A small circular piece of the tissue construct (d: 4mm) was then
excised for imaging under two-photon microscopy. With the addition of the substrate (CEC), we
detected an increase in fluorescent intensity in the collagen gel (Figure 4-5A). The fluorescent
intensity increased linearly with time (Figure 4-5B). These results suggest that two-photon
microscopy can be utilized to detect and localize CYP 1 A2 activity in an engineered hepatic
tissue in vitro based on fluorescence produced by the conversion of CEC into CHC.
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Figure 4-5. (A) Flourescence images of neonatal hepatocytes in collagen gel in vitro. Cytochrome P450 activity wasmeasured by addition of 30gM of CEC and flourescence images were taken at regular time intervals with a two-photon laser scanning microscope. Flourescence intensity correlated with the amount of CHC. (B) Plot offlourescence intensity vesus time revealed a linear increase in the CHC produced.
Discussion
In this study we developed a novel and non-invasive imaging method to quantitatively assess the
functional performance of primary hepatocytes. Cytochrome P450 (CYP450) activity in
hepatocytes was used as a surrogate for hepatic function since one of the primary objective of
livers is to metabolize xenobiotics. Cytochrome P450 is a large family of hemoproteins that
mediates the metabolism of both endogenous and exogenous compounds. We investigated the
de-ethylation reaction of 3-cyano-7-ethoxycoumarin (CEC) into 3-cyano-7-hydroxycoumarin
(CHC) that is mediated by CYP450 isoform 1A2. The reaction product can be easily monitored
and readily distinguished from the substrate due to the strong blue fluorescence emitted by CHC.
We first determined the two-photon characteristics of CHC in solution in order to identify the
optimal excitation wavelength. At 810 nm excitation wavelength, CHC is maximally excited
while CEC is minimally excited. For validation of CYP450 activity, we used primary neonatal
hepatocytes and exposed the cells to CEC. We found that at baseline, neonatal hepatocytes have
minimal CYP450 1A2 activity with little of the CEC converted into CHC. In contrast, neonatal
hepatocytes treated with P-napthoflavone showed a much high rate of CHC production. The
result obtained from imaging was in good agreement with quantitative PCR data showing
substantial up-regulation of the cytochrome P450 1Al and 1A2 isoforms in the induced neonatal
hepatocytes.
Our results further indicate that hepatocytes when grown three-dimensionally in a collagen gel
retained their cytochrome P450 activity. This result is not surprising in light of a number of
studies in literature suggesting that the microenvironment (such as the extracellular matrix) is
important for hepatic functions70. The novelty of our technique is that it is imaging based and
non-invasive, thus it enables repeated measurements over long periods of time. In addition, the
stabilization of photon count when the induced cells were exposed to a specific inhibitor of the
cytochrome P450 1A2 isoform demonstrates another unique advantage of our method - the
ability to make real-time, dynamic measurements, which is impossible for most currently
available methods that require "off-line" processing of culture media, cell lysates, or tissue
samples. Imaging with multi-photon laser scanning microscopy also offers us the advantage to
directly interrogate the CYP450 activity in tissue-like structure. Multi-photon microscopy has the
advantages of reduced light scattering, increased three-dimensional resolution and decreased
photo damage52. These intrinsic properties of multi-photon microscopy enable the imaging of
liver-like tissue with high penetration depth.
CEC and its metabolic product CHC are freely diffusible across the cell membrane, and this
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makes possible the continuous monitoring of CHC in the supematant. However, this property
may potentially be a drawback for the detection of CYP 1A2 activity in liver tissues. Since these
imaging agents are freely diffusible, they can become diluted in a liver tissue especially in an in
vivo setting with intact blood circulation. An imaging agent that is retained intracellularly may
overcome such a problem. This would also allow for the localization of individual functioning
hepatocytes in a mixed population of cells. To this end, we investigated the de-ethylation
reaction of 4-chloromethyl-6,8-difluoro-7-ethoxycoumarin (CMDiFUEt). The chloromethyl
group reacts with glutathione or other intracellular thiols that results in products that are retained
inside a cell71 . CMDiFUEt is a derivative of coumarin and is a known substrate for cytochrome
P450. We determined the two-photon characteristics of the de-ethylation product of CMDiFUEt,
6,8-difluoro-7-hydroxy-4-methylcoumarin (DiFMU). We identified DiFMU to be excitable by 2-
photon with peak two excitation excitation and emission wavelength at 730nm and 460nm,
respectively (Data not shown). However, we noticed that the two-photon characteristics of
DiFMU are very similar to that of NADH and NADPH72 . Since NADH/NADPH is expressed at
a high level inside a cell, it would confound the quantification of the de-ethylase product of the
CMDiFUEt. Due to this fact, we did not further evaluate the use of CMDiFUEt for assessing
hepatic function.
Our results offer a proof of principle for non-invasive imaging in assessing CYP450 activity in
engineered hepatic tissue. Our imaging technique provides a novel tool to optimize cell source,
scaffold material and design for hepatocyte-based tissue engineering, in regards to
preserving/augmenting hepatic CYP450 function. This technique could also potentially be
adapted to evaluate other important hepatic functions, thus allowing a more comprehensive,
long-term assessment of the survival and function of engineered liver tissues.
Chapter 5 : Metabolic consequences of disrupted VEGFR1
pathway signaling
Portions of this chapter have been taken from:
Tam J, Fukumura D, Shibuya M, Jain RK. VEGFR1 regulates glucose metabolism during diet-
induced obesity. Submitted.
Introduction
VEGFR1 (also called Fltl) is expressed in two forms: a full length membrane protein, and a
shorter, soluble form, consisting of only the receptor but not the intracellular tyrosine kinase
domain 73. Compared to VEGFR2, VEGFR1 has a much higher affinity for VEGF, but its
tyrosine kinase activity is much weaker 74' 75. Both VEGFR1 and VEGFR2 homozygous knock
outs are embryonic lethal76' 77, but mice with only the tyrosine kinase domain of VEGFR1
knocked out were able to develop without overt defects74 . Such findings have led to the
suggestion that VEGFR1 primarily functions as a non-signaling "decoy" receptor that negatively
regulates angiogenesis by sequestering VEGF, thereby decreasing its availability for VEGFR278 .
Several recent studies have shed new light on this matter. While VEGFR1 signaling may not be
necessary during development, it appears to play a positive role in angiogenesis in certain
pathological conditions, including ischemia, inflammation, arthritis, atherosclerosis, wound
healing, and cancer 74 ' 79-81. VEGFR1 is also capable of synergistically amplifying VEGFR2-
driven angiogenesis79, possibly via heterodimer formation and intermolecular
transphosphorylation of VEGFR282
We have determined previously that inhibition of VEGFR2 signaling resulted in decreased body
weight gain in mice fed a high fat diet (Figure 2-2). However, VEGFR2 inhibition is known to
produce many undesirable side effects. We were therefore interested to investigate wither
VEGFR1 inhibition would be a viable alternative. To this end, I evaluated how mice lacking the
tyrosine kinase portion of the VGFR1 protein (VEGFRI(TK)-/-) responded to a high fat diet.
~~' 3-*"mt~mo~i-a~L~l;?iai~~"rr--- ~ -~
Materials and Methods
Animal Models
VEGFR1 tyrosine kinase-knockout mice [VEGFR1(TK)-/-] of mixed C57B1/6 and SV129 strain
background were originally developed at the University of Tokyo, Japan 74 , and subsequently
backcrossed to 99.9% C57B1/6 strain background (N10 equivalent) at the Massachusetts General
Hospital. Strain background was verified by the Jackson Laboratory's Speed Congenic
Development Service (The Jackson Laboratory, Bar Harbor, Maine). Genotyping was performed
by polymerase chain reaction (PCR) analysis, as previously described 74 . Age-matched males
were used for all experiments. Mice were maintained on a 12-h light-dark cycle in a temperature-
controlled barrier facility, with ad libitum access to food and filtered water, unless otherwise
specified.
Genotyping
VEGFR1(TK)-/- animals were genotyped by polymerase chain reaction (PCR) using the
following primers: forward (5'-ACCCTCTGTACCTGGTCAATTGATGCA-3'), reverse (5'-
TGCAAACTCCCACTTGCTGGCATCATA-3'), and neo gene (5'-
GCTAAAGCGCATGCTCCAGACTGCCT-3').
Body composition and food intake
Male, 7 week old mice were given either standard chow diet (Prolab Isopro RMH 3000, PMI
Nutrition International, Brentwood, MO), or a 60% fat diet (D12492, Research Diets, New
Brunswick, NJ), and monitored for the next 10 weeks. Body weight and amount of food was
measured weekly. Food spillage was not taken into account. At the end of the experiment, the
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animals were fasted overnight then weighed and euthanized, and the inguinal, perigonadal, and
perirenal fat pads, as well as the livers were excised and weighed.
Glucose homeostasis
Glucose (GTT) and insulin tolerance tests (ITT) were performed after 8 and 9 weeks on the diet,
respectively. Mice were fasted for 16 hours (5pm - 9am) for GTT, or 3 hours (9am - 12pm) for
ITT. Glucose (0.75 mg/g body weight) or insulin (1U/kg body weight) was administered by
intraperitoneal (ip) injection, and tail blood was sampled at 0, 15, 30, 60, 90, and 120 minutes
after administration of glucose/insulin. Blood glucose levels were measured using a Precision
Xtra glucose meter (Abbott Diagnostics, Bedford, MA). Glucose tolerance was evaluated by
calculating the area under the curve (AUC) for each mouse according the following equation:
AUC = (T, - T)x - +min (Glc,, ,Glc,,)- GicTn=1 2
Where Glc is glucose concentration, T is time, n is the time point number, and min(GlcT,Glcrn+)
is the lower of two consecutive glucose concentrations 83. This equation adjusts for differences in
fasting glucose levels, so that the evaluation is based on incremental area above the fasting
baseline. For plasma insulin measurements, animals were fasted overnight, then plasma was
collected by tail bleed at 0 and 30 minutes after ip injection of 0.75 mg/g body weight glucose,
and stored at -80'C until used. Plasma insulin concentration was determined using the Ultra
Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL).
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Adaptive thermogenesis
Mice were placed in a cold room and exposed to 40 C ambient temperature for 24 hr, with free
access to food and water. Body temperature was measured at regular intervals by scanning an
implanted transponder.
Gene Expression
Immediately following excision, liver tissue was snap frozen and stored in liquid nitrogen until
used. Total RNA was extracted using the RNeasy Mini kit (Qiagen, Valencia, CA). cDNA was
synthesized using TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City,
CA). Gene expression was determined by real-time quantitative PCR (qPCR) using the 7300
Real-Time PCR System and Power SYBR Green PCR Master Mix (Applied Biosystems). Primer
sequences are listed in
Table 5-1. Primers were designed using Primer Express (Applied Biosystems) or Primer3
(Whitehead Institute, Cambridge, MA), and purchased from Integrated DNA Technologies
(Coralville, IA). Primer efficiency was validated using standard curves generated from 10-fold
dilutions of mouse liver cDNA. Samples were analyzed in triplicates, and the gene expression
level for each sample was normalized to the corresponding glyceraldehydes-3-phosphate
dehydrogenase (GAPDH) expression level, to control for loading differences. Negative controls
were performed for each sample using non-reverse-transcribed RNA.
Table 5-1. Primers for qPCR.
Gene Forward primer (5'-3') Reverse primer (5'-3')
G6Pase CATGCAGAGTCTTTGGTATTTAAAGTCA GGCCTCACAATGGGTTTCAG
PEPCK TCACCATCACCTCCTGGAAGA TGGTTCCGCGTCCTGC
GAPDH AAGAAGGTGGTGAAGCAGGCA TGCTGTTGAAGTCGCAGGAGA
G6Pase, glucose 6-phosphatase; PEPCK, phosphoenolpyruvate carboxykinase; GAPDH, glyceraldehydes-3-
phosphate dehydrogenase.
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Bone marrow transplantation
Implantation of bone marrow cells was performed as previously described 84. Bone marrow cells
were obtained by flushing the tibias and femurs of age -matched donor mice (VEGFR1 tyrosine
kinase knock out, or wild type littermates) with phosphate buffered saline. The bone marrow
cells were implanted in recipient mice immediately. Recipient mice were lethally irradiated with
two doses of 6.0 Gy (24 hours between each dose) to eradicate all existing bone marrow cells.
Fractionated irradiation was used to minimize gut toxicity. Within 24 hours after the last dose of
radiation, 2x10 6 donor bone marrow cells were injected into the tail vein. Following the
implantation of bone marrow cells, 8 weeks were allowed for the reconstitution of bone marrow
in the recipients, prior to the commencement of other experimental procedures.
Immunohistochemistry
Adipose tissue, liver, and pancreas samples were collected from freshly euthanized animals,
fixed in 4% paraformaldehyde at 4 OC overnight, then embedded in paraffin. 10m sections were
cut and mounted on glass slides. For staining of cultured cells, the cells were fixed with 4%
paraformaldehyde for 15-30 minutes at room temperature (RT). Expression of various markers
was identified by specific staining, as described below. Macrophage content and islet size were
quantified using custom-written computer scripts.
Tissue section (paraffin-embedded) staining protocol
1. Deparafinization:
3x3min Xylene
2x3min 100% Ethanol (EtOH)
2x3min 96% EtOH
2x3min 70% EtOH
2x2min H20
2. Antigen retrieval:
Boil in Dako Target Retrieval solution (Dako, Carpinteria, CA) for 10 min.
3. Wash 3x3min in PBS.
4. Block with 3% BSA in PBS for 1 hour at room temperature.
5. Dilute primary antibody [anti-F4/80 antibody (Serotec, MCA497BB), or anti-insulin
antibody (R&D systems, MAB 1417)] 1:100 in 3% BSA, apply to tissue sections,
incubate overnight at 4'C.
6. Wash slides 3x3min with PBS.
7. Apply fluorescently labeled secondary antibody diluted 1:200 in PBS onto the slides, and
incubate for 1 hour at room temperature.
8. Wash 3x3min with PBS.
9. Apply VECTASHIELD mounting medium with DAPI (Vector Laboratories), coverslip
and store at -20'C until use.
Statistical analysis
Results are presented as the mean + standard error (SE). Student t test (equal variances not
assumed) was used to evaluate statistical significance (defined as P < 0.05).
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Results
Diet induced obesity in VEGFRI(TK)-/- mice
C57B1/6J and VEGFR1(TK)-/- mice of mixed strain background (C57B1/6J and 129S4/SvJae)
were fed a 60% high fat diet (HFD), and their body weights were monitored at regular intervals.
HFD treated VEGFR1(TK)-/- mice gained more weight than C57B1/6J mice, while
VEGFRI(TK)-/- and C57B1/6J mice that were fed a standard low fat diet (LFD) had similar
body weights (Figure 5-1A). Since the VEGFR1(TK)-/- mice are from a mixed strain
background, we bred mice heterozygous for the Fltl mutation, and repeated the experiment using
homozygous littermates in order to control for strain background differences. VEGFR1 (TK)-/-
mice were significantly heavier than their wild type (WT) littermates after 1 week of high fat diet,
and remained so for the duration of the experiment (Figure 5-1B). Food consumption was
monitored in the VEGFR1(TK)-/- and WT littermates by weighing the remaining food at regular
intervals, surprisingly VEGFR1(TK)-/- mice consumed significantly less food than their WT
littermates (Figure 5-1C). These results show that VEGFRI(TK)-/- mice become more obese
than WT when fed a high fat diet, and that this increased obesity was not caused by hyperphagia.
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Figure 5-1. VEGFR1(TK)-/- on high fat diet. (A) Body weights of C57B1/6J and VEGFR1(TK)-/- mice (male, 9-12
weeks old at time 0) on normal (LFD) or a high fat (60% kcal) diet (HFD). VEGFR1(TK)-/- mice gained more
weight on HFD than WT mice, while the difference between VEGFR1(TK)-/- and WT mice on LFD was negligible.
(B) Body weights of VEGFR1(TK)-/- and WT littermates (male, 7 weeks old at time 0) on HFD. VEGFR1(TK)-/-
mice gained significantly more weight than WT littermates. (C) Food (HFD) consumption by animals in described
in (B), measured in grams of food per animal per day. WT animals consumed more food than their VEGFR1(TK)-/-
littermates, despite the higher body weight gain in the latter. Data presented as mean ± s.e.m. *p < 0.05).
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Fat tissue macrophage content in VEGFRI(TK)-/- mice
VEGFR1 is highly expressed by cells of the monocyte/macrophage lineage 73, and is involved in
multiple aspects of macrophage biology, including chemotaxis towards VEGF74, cytokine
production"8 , and osteoclast development86' 87. Several recent studies have highlighted the
important role of fat tissue macrophages in obesity. Whole genome expression analyses revealed
that, out of the genes that are most up-regulated in obese animals, 30 - 59 % correspond to
proteins that are traditionally associated with macrophages 29, 30. Furthermore, obesity is
associated with macrophage accumulation in adipose tissue, and the percentage of fat tissue
macrophages increases linearly with the degree of obesity29' 88. Bone marrow transplant studies
revealed that the vast majority (85%) of adipose tissue macrophages originated from the bone
marrow29. Adipose tissue macrophages are also a significant source of inflammatory molecules,
responsible for almost all TNFa expression in fat tissue, and significant amounts of iNOS and
IL-6 as well29. Paradoxically, many of these fat tissue cytokines are known to have anti-
adipogenic effects 89-91. In light of these reports, I hypothesized that VEGFR1 signaling
deficiency would lead to impaired recruitment of macrophages from the bone marrow to fat
tissue. To test this hypothesis, I quantified and compared fat tissue macrophage content between
HFD-fed VEGFR1(TK)-/- mice and their WT littermate controls.
Epididymal and inguinal fat pads were harvested from the mice described in Figure 5-1B. The fat
pads were fixed with paraformaldehyde, embedded in paraffin, and cut in 10 pm sections.
Macrophages were identified by staining with the F4/80 antibody. For quantification, a
fluorescent secondary antibody was used to identify areas of positive F4/80 staining, while cell
nuclei were identified by fluorescent DAPI staining. This allowed the two types of staining to be
imaged separately using microscope filters of appropriate wavelengths. Images of the F4/80 and
DAPI staining were binarized, and macrophage content was determined by calculating the ratio
between the area of nuclei that overlaps with F4/80 staining and the total nuclei area in each
image (Figure 5-2). The area (instead of number) of nuclei was used, because nuclei that are
located close together could be mistakenly counted as a single nucleus by the computer. So long
as the distribution of nuclear size is similar between macrophages and other cell types in the fat
tissue, the ratio between total nuclei area should be an accurate surrogate for the ratio between
cell numbers. Image binarization and quantification were carried out using MatLab (The
MathWorks, Natick, MA).
6 - 16 non-overlapping images were analyzed for each fat tissue sample, the macrophage content
quantification results were averaged for each mouse, then compared between genotypes. There
was no significant difference in macrophage content in the epididymal fat pad between
VEGFR1(TK)-/- mice (45 ± 10%, mean + 95% confidence interval) and their WT littermates (35
+ 9%). There were very few macrophages in the inguinal fat pads of either genotype. These
results show that, contrary to my initial hypothesis, disruption of the VEGFR1 signaling pathway
did not lead to a reduction in fat tissue macrophage content.
Figure 5-2. Fat tissue macrophage content quantification. (A) Macrophage staining - F4/80 antibody conjugated to
fluorescent secondary antibody. (B) DAPI nuclear staining on the same slide. (C) combined image of f4/80 and
DAPI staining. (D) Binary image of f4/80 staining pattern. (E) Binary image of DAPI staining pattern. (F) Image of
DAPI staining masked by the binary f4/80 image [i.e. (D) as a mask on (E)], retaining only the nuclei that overlap
with F4/80 staining. Macrophage content was calculated as the ratio between nuclei area in (F) compared to (E).
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Phenotype change in VEGFRI(TK)-/- mice of C57Bl/6J background
After the VEGFR1(TK)-/- mice were backcrossed to the C57B1/6J background, I repeated the
HFD experiment. To my great surprise, there was no significant difference between
VEGFR1(TK)-/- and WT mice in body weight (Figure 5-3A), food intake (Figure 5-3B), or body
composition (Figure 5-3C) through 10 weeks of HFD.
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Figure 5-3. Body weight (A), food intake (B), and body composition (C, weights of inguinal, perigonadal, and
perirenal fat pads, as well as the liver, in proportion to total body weight) of male, HFD-fed VEGFR1(TK)-/- (filled
symbols) and WT (open symbols) mice. There was no significant difference between VEGFR1(TK)-/- and WT in
any of these measurements. All animals were 7 weeks old at time 0.
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Lack of VEGFR1 signaling causes impaired glucose tolerance during diet-induced obesity
Despite the similar body weights, glucose tolerance (after 8 weeks of HFD) was significantly
impaired in VEGFR1(TK)-/- mice, compared to WT controls (Figure 5-4A). On the other hand,
there was no significant difference in insulin tolerance between the two genotypes (Figure 5-4B).
To account for the possibility that a difference in insulin tolerance may become evident at a
lower insulin dose, we repeated the ITT at lower insulin dosages (0.75U/kg and 0.5U/kg body
weight), but there was still no significant difference between genotypes (not shown). After 8
weeks of HFD, WT and VEGFR1(TK)-/- mice had similar plasma insulin levels in the fed and
fasted states (Figure 5-4C), as well as following glucose challenge (Figure 5-4D). There were
also no noticeable differences in liver histology (not shown). Hepatic expression of the two main
regulatory enzymes of gluconeogenesis - phosphoenolpyruvate carboxykinase (PEPCK) and
glucose 6-phosphatase (G6Pase) did not differ significantly between the two genotypes (Figure
5-4E). The impaired glucose tolerance only occurred in HFD-fed animals: VEGFR1(TK)-/- and
WT mice on normal chow diet had similar responses to GTT (Figure 5-4F).
We examined the pancreata from both genotypes for morphological differences (Figure 5-5).
There was no significant difference in the average area of insulin-positive islets between HFD-
fed VEGFR1(TK)-/- animals compared to WT controls (Figure 5-5B). Since macrophages are
involved in pancreatic islet angiogenesis, development, and maintenance 92' 93, we also examined
the macrophage content of the pancreata to see if macrophage recruitment to the pancreas was
affected by the deficiency in VEGFR1 signaling. We found no significant difference in
pancreatic macrophage content between the two genotypes (Figure 5-5D).
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Figure 5-4. Glucose homeostasis in male VEGFR1 (TK)-/- (filled symbols) and WT (open symbols) mice after 8
weeks of high fat diet. (A) Intraperitoneal glucose tolerance test (GTT), and area under the curve (AUC) calculated
from GTT data. Glucose tolerance was significantly impaired in VEGFR1(TK)-/- mice. (B) Intraperitoneal insulin
tolerance test showed no significant difference between the genotypes. (C) Fasted and fed plasma insulin
concentration after 8 weeks of HFD. (D) Plasma insulin concentration after overnight fasting (time 0), and 30 min
after glucose challenge. There was no significant difference in either of these measurements, or the fold change in
insulin at the 30 min time point (relative to time 0). (E) Hepatic expression of genes involved in gluconeogenesis. (F)
In animals fed standard chow, glucose tolerance was similar between VEGFR1(TK)-/- and WT mice. * P < 0.05.
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Figure 5-5. Pancreas morphology. (A) Pancreatic islet showing positive insulin staining (green). (B) No significant
difference in mean pancreatic islet area between VEGFR1(TK)-/- and WT mice after 8 weeks of HFD. Averages
were taken from over 290 individual islets and from over 11 animals for each genotype. (C) Pancreatic macrophage
showing positive staining for ER-MP23 (red). Nuclei stained with DAPI (blue). (D) No significant difference in
pancreatic macrophage content after 2 weeks of HFD. Averages taken from at least 5 randomly selected 10x fields
for each pancreas, 4 pancreata for each genotype.
To account for the possibility that insulin production capabilities have began to decline at this
late time point due to chronic obesity, we repeated the plasma insulin measurements in animals
fed HFD for only 2 weeks. Even at this early time point, VEGFR1(TK)-/- mice had significantly
higher fasting plasma insulin levels, and a higher fold-change in insulin following glucose
challenge (Figure 5-6A). Plasma glucose levels were also elevated during GTT (Figure 5-6B),
but there was still no significant difference in ITT results (Figure 5-6C).
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Figure 5-6. Glucose homeostasis in male VEGFR1 (TK)-/- (filled symbols) and WT (open symbols) mice after 2
weeks of high fat diet. (A) Plasma insulin concentration after overnight fasting (time 0), and 30 min after glucose
challenge. VEGFR1 (TK)-/- mice had significantly elevated fasting insulin, and significantly lower fold change in
insulin 30 min after glucose challenge. (B) Intraperitoneal glucose tolerance test (GTT), and area under the curve
(AUC) calculated from GTT data, showing significantly elevated glucose concentrations during GTT in
VEGFR1(TK)-/- mice. (C) Intraperitoneal insulin tolerance test showed no significant difference between the
genotypes. * P < 0.05.
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Bone marrow transplantion
To determine the role of bone marrow-derived cells in HFD-induced obesity and GTT
impairment, the HFD and glucose metabolism studies were repeated in bone marrow
transplanted mice i.e., lethally irradiated WT recipient mice rescued by bone marrow from
VEGFR1(TK)-/- (VEGFR1-BMT) or WT (WT-BMT) mice. As shown in Figure 5-7A, lack of
VEGFR1 signaling in bone marrow-derived cells had no effect on body weight, and did not
reproduce the markedly impaired glucose tolerance exhibited by VEGFR1 (TK)-/- mice (Figure
5-7B).
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Figure 5-7. Abnormality in glucose tolerance was not caused by bone marrow-derived cells. (A) HFD-fed
VEGFR1-BMT and WT-BMT mice had similar body weights. (B) Glucose levels during GTT were similar between
VEGFR1-BMT and WT-BMT mice, as was the AUC calculated from GTT data. * P < 0.05.
Adaptive thermogenesis
Mice genetically deficient for P1GF have been reported to have less brown fat and exhibit an
impaired ability to generate heat in a cold environment (adaptive thermogenesis) 94. To test the
capacity for adaptive thermogenesis in VEGFR1(TK)-/- mice, VEGFR1(TK)-/- mice and WT
controls were kept at 4'C for 24 hours, with regular monitoring of body temperature. No
significant difference in body temperature between the two genotypes was detected (Figure 5-8).
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Acidified drinking water altered metabolic phenotype
Due to a fortuitous change in our institution's animal husbandry policy, the drinking water was
changed from filtered tap water to acidified water for some of our animals. To our surprise, this
significantly altered the animals' response to HFD. On acidified water, HFD-fed VEGFR1 (TK)-
/- mice gained less weight (Figure 5-9A) while eating less (Figure 5-9B) than WT mice. WT
animals also had a higher percentage of perigonadal fat (Figure 5-9C). Despite their lower body
weights, the VEGFR1 (TK)-/- mice had elevated glucose levels after fasting and during GTT
(Figure 5-9D), however there was no significant difference in AUC (which is adjusted for
baseline levels, as described in the methods section), indicating that the elevated baseline (fasting)
levels could account for the higher glucose levels during GTT. Insulin tolerance remained similar
between the two genotypes (Figure 5-9F). The differences in body weight and fasting glucose
only occurred on HFD, as these measurements were similar between VEGFR1(TK)-/- and WT
mice when they were fed acidified water and standard chow (not shown).
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Figure 5-9. Acidified drinking water altered metabolic phenotype. (A) VEGFR1(TK)-/- (filled symbols) gained
significantly less weight than WT (open symbols) mice on acidified water and HFD. (B) VEGFR1(TK)-/- mice also
ate less than WT. (C) Weights of inguinal, perigonadal, and perirenal fat pads, as well as the liver, in proportion to
total body weight. Perigonadal fat pads accounted for a significantly higher portion of total body weight in WT
compared to VEGFR1(TK)-/- mice. The difference in percentage of inguinal fat did not reach statistical significance
(P - 0.07). (D) Glucose levels were elevated during GTT in VEGFR1(TK)-/- mice, despite their lower body weights,
however there was no difference in AUC, due to the higher baseline value for VEGFR1(TK)-/- mice. (E) Insulin
tolerance was similar between the two genotypes. * P < 0.05.
To determine whether acidified water was primarily a transient environmental factor (e.g. by
affecting appetite), or if it has more long-lasting effects, we took mice born to dames given
filtered tap water, then weaned them onto acidified water, and repeated the HFD experiment,
monitoring body weight and food intake for the next 10 weeks. The mice that were weaned onto
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acidified water gained more weight on HFD than mice born to acidified water (Figure 5-10A),
even as the former ate less than the later (Figure 5-10B). These results suggest that the effects of
acidified water go beyond merely affecting appetite. One possible explanation for this
phenomenon is that exposure to acidified water may contribute to "metabolic imprinting" -
where environmental factors during early development have lasting effects on an individual's
energy metabolism 95
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Figure 5-10. (A) Body weight ofHFD-fed VEGFR1(TK)-/- mice born and raised on filtered tap water ("Tap", solid
squares), born to dames on filtered tap water then weaned onto acidified water ("WeanAcid", open triangles), or
born and raised on acidified water ("Acid", open squares), then given HFD starting from 7 weeks of age. Switching
to acidified water later in life did not have the same affect as being born to dames on acidified water, as the mean
body weight of HFD-fed mice weaned onto acidified water was in-between those always maintained on filtered
water or acidified water. (B) Food intake under the three aforementioned conditions. There was no significant
difference in food intake between the Tap and Acid groups, while the WeanAcid group ate significantly less then
either of the other groups.
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Discussion
In this study we showed that deficient VEGFR1 signaling causes impaired glucose tolerance in
mice with diet-induced obesity. Evidence of impaired glucose metabolism presented as early as
two weeks after HFD-feeding, at which time VEGFR1(TK)-/- animals showed signs of basal
insulin resistance with significantly elevated fasting insulin and glucose levels. In contrast, there
was no significant difference in insulin tolerance test results or in hepatic expression of
gluconeogenic genes.
Previous studies have demonstrated similar impairment in glucose tolerance in mice with genetic
VEGF deficiencies in the whole pancreas 96, or specifically in P-cells 97, and the impairment is
thought to be caused by defective transport of insulin across vascular endothelial cells. The
similar phenotypes between those prior studies and our data from VEGFRI(TK)-/- mice suggest
that VEGFR1 may be involved in insulin transport in endothelial cells. More detailed studies of
insulin transport in VEGFR1(TK)-/- endothelial cells is needed to verify this possible mechanism.
Obesity is usually accompanied by increased P-cell mass, which has a strong linear correlation
with body weight 98. The similarity in pancreatic islet size between VEGFR1(TK)-/- and WT
mice suggests that deficient VEGFR1-signaling did not impair P-cell mass expansion in
VEGFR1(TK)-/- mice. This result is also similar to reports that lack of VEGF in the pancreas did
not impair islet P-cell mass expansion 96' 97
It should be noted that systemic inhibition of VEGF in adult mice has been reported to have the
opposite effect of improving glucose tolerance 99, and pharmaceutical inhibition of PlGF did not
reproduce the metabolic phenotypes exhibited by mice with genetic P1GF deficiency 36. Thus the
transient effects of pharmaceutical agents on metabolic parameters may not always be parallel to
phenotypes caused by life-long genetic deficiencies. Imperfect delivery/efficacy of
pharmaceutical agents may also miss the phenotypes induced by the complete block with genetic
alterations. Nevertheless, the impaired glucose tolerance demonstrated both in our study (with
VEGFR1(TK)-/- mice) and in previous reports (with pancreas-specific VEGF deficient mice)
suggest that possible adverse affects on glucose metabolism should be considered when applying
anti-angiogenic therapies, especially where such therapies were targeted towards treatment for
obesity/diabetes.
In this study, VEGFR1(TK)-/- and WT mice had similar body weights when they were fed HFD
and filtered tap water. This result is not in agreement with the report by Lijnen et a136 that PlGF-
deficient mice gained less weight on HFD. There are several possible explanations for this
difference. PlGF is one of several ligands for VEGFR1, thus it is possible that in P1GF deficient
mice other ligands (such as VEGF or VEGF-B) may still be signaling through VEGFR1, while
the VEGFR1(TK)-/- mice used in our study are completely lacking in VEGFR1 signaling. Strain
background may also be a factor - the PlGF knockout animals used by Linjen et al were of Swiss
and 129SV background, while the animals used in our study were of C57BL/6 background.
Finally, our data showing lower body weight (consistent with the results of Lijnen et al) in
VEGFR1(TK)-/- mice fed HFD and acidified drinking water shows that the metabolic phenotype
of the VEGFR1(TK)-/- mice is very sensitive to confounding environmental factors. Thus it is
possible that environmental differences between animal facilities could account for the different
observations.
Obesity is associated with the accumulation of bone marrow-derived macrophages in adipose
tissue 29, 88. Adipose tissue macrophages are a significant source of inflammatory molecules,
responsible for almost all TNFa expression in fat tissue, and significant amounts of iNOS and
IL-6 as well29. Bone marrow-derived macrophages have been shown to have significant affects
on the development of diet-induced insulin resistanceloo. VEGFR1 has a major role in the
recruitment and function of bone marrow-derived cells81' 101, and also mediates various
functionalities in cells of the monocyte/macrophage lineage, including chemotaxis towards
VEGF 102 and cytokine production l0 3. To determine whether the metabolic phenotypes observed
in VEGFR1(TK)-/- mice were caused by the lack of VEGFR1 signaling in bone marrow-derived
cells, we performed bone marrow transplantation studies using bone marrow from both
VEGFR1(TK)-/- and WT mice. HFD-fed VEGFR1-BMT and WT-BMT mice showed similar
body weight and glucose tolerance, indicating that VEGFR1 signal deficiency in bone marrow-
derived cells was not the cause of the metabolic phenotypes observed in VEGFR1 (TK)-/- mice.
The investigation into why acidified water causes VEGFR1(TK)-/- mice to eat less and gain less
weight on HFD than WT mice is beyond the scope of the current study, although future work to
examine this curious phenomenon may yield interesting insights regarding the complex gene-
environment interaction that governs energy homeostasis. It is unlikely that a change in appetite
alone could account for the reduced weight gain in VEGFR1(TK)-/- mice fed HFD and acidified
water, because their food intake was similar to that of VEGRI(TK)-/- mice fed HFD and filtered
tap water (P>O. 18), and because mice that were born to dames given filtered tap water, then
weaned onto acidified water were partially protected from the weight reducing effect of the
acidified water (Figure 5-10). It has been reported more than two decades ago that acidified
drinking water causes reduced body weight in mice1 04 . The precise underlying mechanism is
unknown, but may be due to effects of excess ion intake on the gut flora104 . Despite this
documented side-effect, acidified drinking water is widely used for mouse husbandry in many
research facilities. The results in this study show that acidification of drinking water is a
significant confounding factor that should especially be avoided in studies relating to metabolic
phenotypes.
Chapter 6 : Mathematical modeling of energy balance
regulation in mice by the leptin pathway
Portions of this chapter have been taken from:
Tam J, Fukumura D, Jain RK. A mathematical model of murine metabolic regulation by
leptin: energy balance and defense of a stable body weight. Cell Metabolism, accepted.
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Introduction
Obesity, with its many well-known co-morbidities, has become so prevalent that it is often
described as a global epidemic. It is a notoriously obstinate disease - non-surgical treatments
directed towards long-term body weight reduction are seldom effective. Energy homeostasis is
regulated by centers in the central nervous system (CNS), which receive and integrate
information conveyed by signals from peripheral organs (such as fat, gut, and the endocrine
pancreas), then send out efferent neural and hormonal signals to regulate food intake and energy
expenditure 05', 106. Acute changes in an individual's net energy balance are counteracted by
opposing changes in food intake and/or energy expenditure which minimize changes in body
weight11, 107 . This system is remarkably robust, so that even though energy intake and
expenditure can both fluctuate substantially over time, total body weight is maintained within a
relatively narrow range.
These observations have led to the "set-point" hypothesis - the idea that in each individual there
is an explicit body weight set-point, deviations from which are vigorously opposed by
compensatory responses, until the set-point body weight is restored. The nature of this set-point
is unknown - no physiological factor representing the set-point has ever been identified. This
elusive set-point is believed to have a major genetic component, but some have proposed
recently that the set-point may be altered by environmental factors, especially during early
development 95. While the difficulty in reversing obesity is often cited as support for the set-point
hypothesis, the fact that obesity could develop in the first place is often used to argue against this
hypothesis. Opponents of the set-point hypothesis argue that there is little active regulation of
body weight, and that the apparent stable body weight is primarily a steady state outcome
determined by environmental factors such as diet and life style (the "settling point" hypothesis).
In essence, proponents of the set-point hypothesis attribute obesity mostly to intrinsic
physiological factors, whereas proponents of the settling point hypothesis believe external
environmental factors to be predominant. The debate over which hypothesis is most consistent
with experimental and clinical data has lasted several decades, and is still on-going -111
This controversy underscores the fact that, despite the impressive progress made over the past
few decades in unraveling many of the molecular pathways involved in energy regulation, we
still have a rather murky understanding of how all the pieces fit together to function as an
integrated system. Most previous mathematical models of metabolic energy regulation have not
explicitly modeled the neuroendocrine feedback system that maintains energy homeostasis. In
order to address this deficiency, we have developed a mathematical model that simulates the
physiological system that regulates energy metabolism. This model could complement
experimental efforts in answering certain fundamental questions regarding obesity, such as: (i)
how different arms of the energy regulatory system interact to produce a stable body weight; (ii)
how perturbations such as increased caloric density in food or leptin resistance could affect
overall energy balance; and (iii) why there is such wide variation between different individuals
subject to similar metabolic environments. We have decided to model the mouse, instead of
humans, because mice can be subjected to much more rigorous and invasive experimental
investigation, and also because the availability of transgenic mice allows the roles of specific
molecular pathways to be studied more thoroughly than is possible in human subjects.
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One of the best-characterized arms of the energy regulatory system is the leptin pathway. Leptin
is produced by fat cells and secreted into the blood stream. Circulating leptin has effects on some
peripheral organs, including muscles and liver, but its most critical effects are in the CNS
(particularly the hypothalamus), where a low level of leptin serves as a potent starvation signal,
triggering an array of adaptive neuroendocrine responses including hunger/food seeking behavior,
efficient metabolism, and suppressed reproduction 2, 113. When the leptin pathway is disrupted
by mutations in the gene for leptin or its receptor, the body behaves as if it is constantly starving
- resulting in morbid obesity via over-eating and energy hoarding. Although disruptions in the
leptin pathway produce very dramatic results, they are also quite rare. Instead, most cases of
chronic obesity are characterized by high circulating leptin levels as well as leptin resistance,
such that the dose-response towards leptin is diminished compared to leaner individuals.
We have developed this physiologically-based model is to simulate the effects of leptin on the
energy regulatory system. The model reproduces key characteristics of this system, such as the
ability to counteract changes in environmental factors to minimize variations in body weight, and
the failure of this ability when the leptin pathway is disrupted. Variations in specific parameters
in the model are able to simulate the wide variations in susceptibility to diet-induced obesity
among different in-bred mouse strains 114. Our model revealed that multiple body weight steady
states are possible under certain conditions - a potential mechanism contributing to the well-
known obstinacy of obesity, with important clinical implications. We also used our model to
evaluate the long-standing controversy regarding body weight regulation, and found that a
unified model combining aspects of both leading hypotheses ("set-point" vs. "settling point"
hypotheses) is most consistent with experimental data.
Methods
We developed a system of ordinary differential equations to describe the effects of leptin on
various aspects of energy metabolism (Figure 6-1). To evaluate whether a regulatory system
based on a body weight set-point is consistent with experimental data, we carried out and
compared simulations for two separate systems - with and without control by an explicit set-
point. In adherence to established terminology in the field, we will refer to these as the "set-
point" and "settling point" models. Because of the well-documented effects of strain background,
age, and gender on energy metabolism, we only used data from adult (6 - 24 weeks of age) male
mice of the C57B1/6J background, fed standard mouse chow, for the derivation of model
parameters, unless otherwise noted.
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Major assumptions
The following are the major assumptions made in formulating this model:
1) We assumed that energy metabolism responds to leptin concentration, rather than other
possible inputs such as the rate of change of leptin concentration. We make this
assumption because most experimental reports in the literature use leptin concentration as
the basis for analysis, but it should be noted that this may reflect literature bias rather
than any scientific rationale for favoring one mode of leptin regulation over another.
2) This model only considers intermediate time-scales involved in body weight change
(days - weeks). Events that occur on shorter time scales (seconds to hours), such as food
intake, energy absorption from the gut, and leptin production and transport, are assumed
to be both instantaneous and continuous. For the same reason, diurnal variations in leptin
production, food intake, energy expenditure, etc., are generally disregarded. On the other
hand, longer termed changes related to chronic obesity and aging are also not taken into
account in the current model.
3) It is assumed that food intake control is based on food mass, rather than its energy
content. This is because satiety/fullness after a meal typically occurs before the energy
from the food eaten is digested and absorbed, in other words the decision to end a meal is
typically reached before the energy content of that meal is known to the body.
4) This model considers only the energy content of the ingested food. Effects caused by
different macronutrient compositions in the diet are ignored.
5) For this model body weight is calculated as the sum of fat mass (FM) and fat-free mass
(FFM). FFM is assumed to be constant, i.e. all energy input is stored as fat, and all energy
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expenditure is taken from fat. This model is only intended to simulate energy homeostasis
in adults with relatively stable internal organs, bone, and muscle mass.
6) Our model only deals with dietary energy content, ignoring their macronutrient
composition.
Leptin production and transport
We assumed that leptin is produced and secreted by fat cells at a rate roughly linear to total fat
tissue mass, and cleared by the kidney by glomerular filtration 115. This relationship is described
as:
d(Lep plasma X BloodVolum e)d(Lp pl o= FM x R y- GFR x RenClearanc e x Lep plasma [Equation 1]
dt
Where Lepplasma is the plasma concentration of leptin. FM is fat tissue mass. Rsyn is the leptin
synthesis rate - 3.6 ng/100 g fat tissue/min (similar in rats and humans, assumed to be the same
in mice)116, 117. BloodVolume is the total blood volume in a mouse, which varies with body
weight. In this model blood volume is estimated as:
BloodVolum e = (0.022 x BodyWeight + 1.5)ml, which is derived from the report by Yen et al 118
with the assumption that the relationship between body weight and blood volume is linear.
The rate of leptin removal by kidneys (RenClearance) is approximately 25% 115. GFR is the
glomerular filtration rate, we estimated GFR to be -11.85ml/hr by taking the average of GFR
reported in two independent studies using male C57B1/6J mice1 19' 120. For a mouse with -2 ml
total blood volume, this gives a leptin plasma half-life of - 28 min. Literature values for leptin
plasma half-life vary over a very wide range, from 9.4 minutes 116 to several hours112
Plasma leptin enters the brain both by saturable specific receptors and by nonspecific linear
diffusionl 2 1, 122. This relationship is represented as an equation taken from Banks et al 121:
Lep Brain = kl Plasma + k3 (Lep plasma ) [Equation 2]
k 2 + Lep Plasma
Where LepBrain represents whole brain leptin concentration. For the rest of the model, whole
brain leptin concentration is assumed to represent the level of leptin exposed to the energy
regulatory centers of the brain. Banks et al give values of kl = 1.42 ng/g and k2 = 15.6 ng/ml.
From a graph in the same report showing nonspecific transport of leptin, we estimated the value
for k3 to be 0.00272 ml/g.
Leptin uptake into the CNS is not accounted for in the plasma leptin balance equation (equation
1). We believe this simplification is justifiable on the grounds that 1) plasma leptin concentration
(physiological range - 5-40 ng/ml) is typically much higher than leptin concentration in the brain
(in the 1-2 ng/g range); and 2) compared to blood volume (-2 ml in mice), brain mass (-450 mg)
is relatively low, so that the amount of leptin in circulating blood dwarfs the amount of leptin in
the brain.
Settling point model
The leptin pathway is arguably the most powerful regulator of food intake. Hyperphagia (over-
eating) is a predominant result of disruptions in the leptin pathway. Low leptin levels are a potent
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initiator of neuroendocrine starvation responses, while administration of exogenous leptin
(especially when administered to the brain) reduces food intake 23' 124. We used a modified form
of the classic Michaelis-Menten equation to represent this relationship, with the maximum (at 0
leptin concentration) scaled by food intake in leptin knock-out animals:
FoodIntake = k 4  Le Brain [Equation 3]k5 + Lep Brain
In this equation, k4 scales the maximum food intake value, which is obtained when leptin
concentration approaches zero, therefore k4 is equal to food intake in leptin knockout mice. Table
6-1 shows food intake values in leptin knockout (ob/ob or db/db) mice, as reported in several
different studies. Taking the average of these values gives k4 = 5.6 g/day.
Table 6-1. Literature values for food intake in leptin pathway knock-out (ob/ob and db/db) mice.
Food intake Reference
(g/mouse/day)
4.64
5.5
4.5
5.16
8.05 128
6 129
Plasma leptin and food intake values for wild-type (WT) mice from several reports in the
literature are listed in Table 6-2. Leptin concentration in the brain is seldom reported in the
literature, and was not reported in any of the references listed in the table. We calculated brain
leptin concentrations by substituting the reported plasma leptin concentrations into equation 2.
Equation 3 was fitted to brain leptin and food intake data listed in Table 6-2 to obtain k5 = 0.55
ng/g (Figure 6-2A).
Table 6-2. Literature values for leptin levels and food intake in wild-type, young adult C57B1/6J males.
Plasma leptin Brain Leptin Food intake Reference
(ng/ml) (ng/g)* (g/mouse/day)
2.2 0.18 3.6 130#
4 0.3 3.7 130#
2.25 +  0.19 4.5 131
2.5 0.2 4.3 132
* Leptin concentration in the brain was estimated from plasma leptin, using equation 2
# This reference also reported data on mice that were 11-12 months old. That data was not used because the mice
were too old.
+ Average of leptin levels given at two different ages (-2ng/ml at 7 weeks and -2.5ng/ml at 22-39 weeks).
Energy intake (Ei,) equals to food intake multiplied by its metabolizable energy content (Pfood):
Ein = pfoodFoodlntake
= Pfood k4 +Lep a
k, + Lep Brain
[Equation 4]
The relationship between energy expenditure and body weight/leptin levels is less clear, with
seemingly contradictory reports in the literature (Table 6-3). Most studies showed that
exogenous leptin is most effective at low leptin levels, but at normal, well-fed leptin levels,
additional leptin has little effect on energy expenditure. Again we used a modified Michaelis-
Menten equation to describe energy expenditure (Eo,,t) as follows:
[Equation 5]Eout = k6BM 1+k 7  Lep Br,
kg + Lep Brain
Where BM is the total body weight. When leptin level equals zero, this equation becomes [Eout =
k6BM], and describes the linear relationship between body mass and energy expenditure in leptin
knock-out animals 127. Energy expenditure data from various references for mice with disrupted
leptin pathway are listed in Table 6-4. For leptin pathway knockout animals, equation 5 becomes
Eout = k6BM. Taking the average of the data in Table 6-4, we obtain k6 = 10.18 cal/g body
weight/hour.
The other terms model the additional effect of leptin as a saturable function, so that the energy
expenditure-related effects of leptin are most prominent when leptin levels are low, but become
roughly constant at higher levels of leptin (Figure 6-2B).
Table 6-3. Effect of leptin on energy expenditure, according to reports in the literature
Conclusions Reference
Energy expenditure is roughly linear to body weight in genetically obese mice, and higher 127
than lean littermates
Leptin increases energy consumption in ob/ob mice, and in food deprived lean mice 3
Leptin increases energy expenditure of food-restricted lean mice, but when food is
abundant only changes food intake
Leptin infusion reduces fat mass in excess of that caused only by reduction in food intake 134
(presumably by increasing energy expenditure)
Energy expenditure per unit body weight is increased after 3 weeks of leptin administration
in ob/ob mice, but no effect in lean mice
Energy expenditure unchanged by central leptin infusion
Leptin increases energy expenditure (normalized to body size) in ob/ob mice, but not in 128
lean ob+/- mice
No relationship between energy expenditure and body mass (within narrow range: 20-28g)
Table 6-4. Energy expenditure data for leptin pathway knockout (ob/ob and db/db) mice.
Genotype Mean body Energy expenditure Energy expenditure Reference
weight (g) (kcal/day) /body weight (cal/g/day)
Ob/ob 28.2* 6.91 244.8
Ob/ob 35.4* 8.69 244.8
Ob/ob 53.5* 15.1 283.2 18
Ob/ob 37 7.7+ 206.4
Db/db 37.8 9.25+  244.8 12
* When body weight was reported as a range, mean body weight is estimated by averaging the body weights at the
two ends of the range. E.g. For the first entry Ob mice weigh 23.7g at week 6 and 32.7g at week 9, therefore the
average body weight for weeks 6-9 = (23.7+32.7)/2 = 28.2g
+Energy expenditure was calculated from indirect calorimetry data using this equation 139: E = (3.91 + 1.10 RQ) VY2,
where E = energy expenditure (in kcal/min), RQ = respiratory quotient, V0 2 = oxygen consumption (in L/min). RQ
- 0.98 was given in the reference.
When LepBrain approaches infinity, equation 5 becomese Eout = k6BM(1+k 7 ), thus the parameter
k8 determines the maximal asymptote for equation 5. According to Mistry et a1l23, oxygen
consumption (a surrogate measurement for energy expenditure) in ob/ob mice was
approximately 3.0 mlg body weight/hr, while the value for WT mice was - 6.1 ml/g body
weight/hr. Oxygen consumption for WT mice did not increase even after intracerebroventricular
administration of high dose leptin, therefore it can be assumed that the maximal asymptote has
been reached. Using the two values for oxygen consumption in the equation [Eut = k6BM(l+k7)]
gives k7 - 1.
We then used data from WT animals (Table 6-5) to estimate values for k8. Here again brain
leptin concentrations were calculated by substituting the reported plasma leptin concentrations
into equation 2. Equation 5 was fitted to the data listed in Table 6-5, giving k8 = 0.22 ng/g.
Table 6-5. Energy expenditure and corresponding leptin data for wild-type mice.
Body mass Energy* Plasma leptin Brain leptin# Reference
(g) expenditure (ng/ml) (ng/ml)
(kcal/day)
28 11.4 4.4 0.32 140
27.5 9.84 +  4.31 0.28 141
25 10.1 5 0.36 142*
* Estimated from graphs given in the corresponding references
# Estimated values using equation 2
+ Calculated from indirect calorimetry data using the equation E = (3.91 + 1.10 RQ) V02. RQ assumed to be 0.85.
** Data from this reference were from mice of mixed 129Sv-C57B1/6J strain background
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Figure 6-2. Leptin dose-response curves for (A) food intake (g/mouse/day), and (B) energy expenditure (cal/g body
weight/hour) for the settling point model (equations 3 and 5). Solid curves represent calculated food intake and
energy expenditure according to their corresponding equations, as described in the text. Crosses represent
experimental data (Tables 5-2 and 5-5) used to obtain the corresponding model parameters.
Overall energy balance is given by:
dE (t)
dt En out
k 6BM 1 + k 7  Lep Braink8 + Lep Brain
[Equation 6]
Where E(t) denotes the amount of energy stored as fat at time t.
Body weight is the sum of fat mass (FM) and fat-free mass (FFM):
BM = FM + FFM
[Equation 7]
Where Pfat is the energy density of fat. This equation assumes FFM is relatively constant.
= Pfood k 4
Lep Brain
k
,
+ Lep Brain
E(t)
= - + FFM
Pfat
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Set-point model
We modeled the set-point hypothesis as a feedback system regulated by proportional-integral (PI)
controllers. PI controllers are a well-established class of controllers commonly used in feedback
control systems, mathematically defined by the following equation 43:
c(t) = Kce(t) + ~c j(t)dt + c
Where c(t) is the value, at time t, of the entity being regulated by the controller. Kc is the
proportional gain of the controller. r, is the integral time constant. e(t) is the error signal (i.e., the
difference between the measured value and the desired set point) at time t. cs is the controller's
actuating signal when g = 0 (also known as the "bias signal").
The PI controller was chosen because it is widely used and well-characterized, and because it
fulfills the requirement of the set-point hypothesis that the controlled value eventually returns to
the set-point. Although our analysis was based on simulations using PI controllers, the
conclusions are applicable to any control system that is able to return its output to a state of zero
error. The simplest controller (proportional controller) was not used because proportional
controllers suffer from offset, such that there is always a discrepancy between the response to
either a new set point or to a persistent change in load, thus violating the central tenet of the set-
point hypothesis.
We assume that whole brain leptin level is the measured signal. For the set-point model, food
intake is defined as:
FoodIntake (t) = a (Lep Brain (t) - SetPt )+ a 2 (Lep Brain (t) - SetPt )dt + c , [Equation 8]
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Where SetPt is the brain leptin set-point. The control action in this model is driven by the
difference between brain leptin concentration and the set-point (known as the error signal). For
consistency and ease of comparison, we used the steady-state brain leptin level obtained in our
previous simulation (0.34 ng/g) as the set-point. cj is the amount of food intake when LepBrai,
equals to the set-point (also known as the "bias signal"). Again this is set to be the same as the
steady-state value of the previous model (3.56 g/day).
Similarly, energy output (per unit body weight) can be defined as:
Eou, (t) = BM x a3 (Lep Brain (t) - SetPt ) + a 4 (Lep Brain (t) - SetPt )dt + c 2  [Equation 9]
Where c2 = energy output when LepBrain equals to the set-point, from the steady-state solution of
the previous model, c2 = 16.34 cal/g/hr.
Because of the integral terms in equations 8 and 9, the values for parameters al - a4 cannot
simply be fitted to experimental data as we did for the parameters in the settling point model.
Instead, here we have set physiological upper and lower bounds for food intake and energy
expenditure values, and arbitrary chose values for al - a4 such that the system is stable and does
not oscillate. While the values for al - a4 affect the dynamic behavior of the system, they affect
neither the steady state values nor the conclusions drawn from this model. Food intake is set to a
maximum of 5.6g/day (the average amount of food intake by leptin pathway knockout mice,
Table 6-1), and a minimum of 0. Energy expenditure is set to a minimum of 10.18cal/g/hr
(energy output in leptin pathway knockout mice, Table 6-4), and a maximum of twice this value
(20.36 cal/g/hr, see derivation of equation 5 above for justification).
Other than the food intake and energy expenditure equations, all other equations were kept the
same as the settling point model. Values for each parameter used in this model are listed in Table
6-6.
Table 6-6. Values of model parameters.
Parameter Value Units
kl 1.42 ng/g
k2 15.6 ng/ml
k3 0.00272 ml/g
k4 5.6 g/day
kg 0.55 ng/g
k6  244.32 cal/g body weight/day
k7 1 N/A
ks 0.22 ng/g
Rsyn 51.84 ng/g fat tissue/day
GFR 284.4 ml/day
RenClearance 0.25 N/A
Pfood 3.2 (chow diet) kcal/g
al -0.24 g /ng/day
a 2  -288 g /ng/day
a3  7.2 cal/ng/day
a4  86.4 kcal/ng/day
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There are two key differences between the "settling point" and "set-point" systems, as currently
defined: 1) while the steady-state solution in the settling point system is a product of the
functions governing food intake and energy output, and the various parameters contained in these
functions, the set-point system is driven by the attempt to maintain leptin levels at an explicitly
defined level; and 2) the set-point system is able to return the system to the set-point despite
persistent change in input, which is impossible for a settling point type system.
Our justifications for designing a set-point model that is able to completely eliminate even small
errors are as follows:
1. The prevailing conceptualization of the set-point model depicts a system that does return
to the set-point. This view was shaped mainly by the observation that people who
intentionally try to change their body weight, whether they are trying to lose weight (e.g.
obese persons going on diets) or trying to gain weight (e.g. actors trying to gain weight
for movie parts), are usually able to do so for a short time, but eventually they return to
their original body weight. This led to the conclusion that one's body weight can be
transiently perturbed, but eventually the body weight does return to the set-point.
2. There are experimental examples in some animals of the type of precise control that is
only possible in a set-point system that is able to completely eliminate even small errors.
For example, rats 14 4 and mice 145 appear to be able to maintain their body weights very
well against dilutions in dietary caloric content. In both cases the animals were able to
maintain virtually constant body weights despite up to 50% diet dilution. In mice,
significant weight loss did not occur until diet dilution was so severe (70%) that the
animals began to fall ill and even die145
Interestingly, not all animals are able to maintain their body weights when challenged
with dietary dilution. For example, cats loss weight roughly linearly with the extent of
dilution in their diets 14 6. These animals would not be consistent with a model that
completely returns to the set-point.
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Humans have shown a variety of responses towards dietary dilution. Some people are
able to adjust their meal sizes to maintain stable body weights despite dietary dilutions,
while others are not 47 . It is possible that variations in the relative dominance of the set-
point component versus the settling point component could account for differences
between individuals.
Computational method
Model computations were performed using MatLab (The MathWorks, Natick, MA). Ordinary
differential equations were solved numerically using the Dormand-Prince Runge-Kutta method.
Data fitting was performed by unconstrained nonlinear optimization.
Results
Settling point model
Base-line conditions
The equations for the settling point model were solved, assuming fat free mass of 22g 148, a
standard chow diet (Pfood - 13.4 kJ/g1 49, 150), and an initial fat mass of 2g. Initial leptin
concentrations were calculated using equations 1 & 2 (assuming steady state at time 0 for
equation 1). The model reached steady-state values of - 6.4 g fat mass, 4.6 ng/ml plasma leptin,
and average food intake of 3.6 g/mouse/day. These values are all within the normal range for
male C57/B6 mice112' 127, 148, 151, and were independent of initial fat mass.
Leptin deficiency
When the leptin pathway was completely disrupted (accomplished in the model by setting the
leptin synthesis rate to zero), the model resulted in a mouse with - 73 g body weight at steady
state, and the body weight growth curve was in good agreement with experimental data (Figure
6-3A). Food intake in the simulated leptin knockout (LepKO) mice was higher than wild type
(WT) mice (Figure 6-3B), which is one of the key characteristics of leptin knockout mice.
Energy expenditure in the LepKO mice was lower than WT mice at early time points when the
LepKO mice still had relatively low body weights, but their energy expenditure increased as
body weight increased, eventually overtaking WT mice (Figure 6-3C), which is consistent with
experimental observationsl38' 152. When energy expenditure was normalized against body weight,
WT mice consistently expended more energy per unit body weight than LepKO mice (Figure
6-3D). This is a well-documented phenomenon that has been the subject of some debate1 53
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Figure 6-3. Metabolic consequences of disrupted leptin pathway in the settling point model. (A) Body weight in
simulated WT mice (solid line) compared to leptin knockout mice (dotted line). Crosses: body weight of leptin
knockout mice of C57B16/J background, as reported by the Jackson Laboratory ("Weight gain in WT.V-Lepob/J
mice", http://jaxservices.jax.org/technotes/invivoOl0906.html). Circles: body weight of WT C57B16/J males (J. Tam,
unpublished data). Simulation outcomes for both leptin knockout and WT mice are similar to experimental results.
(B) Simulated food intake in WT versus leptin knockout mice (ob). (C) Total energy expenditure in WT (solid line)
versus leptin knockout (dotted line) mice. (D) Simulated energy expenditure normalized by body weight, in WT
(solid line) versus leptin knockout (dotted line) mice.
Haploinsufficiency in leptin or its receptor also causes obesity, albeit not as severe as
homozygous knockouts 154. In our model, leptin haploinsufficiency can be approximated by
halving the rate of leptin synthesis (disregarding compensatory responses, such as up-regulation
of leptin receptors, that could lessen the impact of genetic haploinsufficiency in leptin). When
leptin synthesis rate was decreased by 50%, percentage body fat increased by about 36% in our
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model, which is remarkably similar to experimental results showing a roughly 30% increase in
percentage body fat in C57B1/6J mice with haploinsufficiency in leptin or its receptor, after
adjusting for age and sex (percentage body fat was 35.2% higher in Leprdb/+ and 23.5% higher in
LepOb/+ mice, no significant difference between the two heterozygotes 54).
It should be noted that the animals used by Chung et al have a different baseline steady-state
(2.7g body fat for widetype mice) than the studies from which we derived our modeling
parameters (-6g body fat for C57 widetypes 148), so more direct comparisons (e.g. in absolute fat
mass) is unfortunately not possible without more information on the experimental conditions
(food intake, energy expenditure, etc. for widetype and heterozygotes).
Compensatory responses to changes in energy balance
The effects of dietary alterations were simulated by setting the metabolizable energy of the diet
to +50% the normal value, respectively. In both cases, the change in diet caused a corresponding
change to a new steady-state body weight (Figure 6-4), and when the dietary energy content
returned to normal, body weight quickly returned to pre-diet values (not shown). This behavior is
expected of a steady state system subjected to a persistent change in input. The changes in
dietary energy content also led to apparent compensatory responses: a decrease in dietary energy
content led to increased food intake and decreased energy expenditure, with the combined effect
of diminishing the decrease in body weight (Figure 6-4A); whereas a rise in dietary energy
content led to decreased food intake and increased energy expenditure, lessening the increase in
body weight (Figure 6-4B). Similar adaptive responses are seen when energy expenditure is
changed (not shown). These compensatory mechanisms that minimize changes in body weight
are well-documented in experimental settings 11, 107 , and are the core foundation of the set-point
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hypothesis. In the system depicted in Figure 6-4 these responses are not corrective attempts to
minimize the difference from an explicitly defined reference (which would be the case for a set-
point control system), rather they are the products of the leptin dose-response curves for food
intake and energy expenditure.
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Figure 6-4. Adaptive changes in response to altered energy intake for the settling point model. Normal diet was
eaten during weeks 0-4, while diet energy content was decreased (A), or increased (B) by 50% during weeks 4-12.
Plasma and brain leptin levels, fat mass, and total body weight decreased during food restriction and increased
during overfeeding, reaching new steady state values. In both cases, food intake and energy expenditure changed in
directions that opposed the change in dietary energy content, so that the change in fat mass was diminished.
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Sensitivity analysis
To test the sensitivity of this model to the model parameters (kl-ks, Rsyn, GFR, and pfood), each
parameter was varied across its physiological range (see Table 6-7 for range and justification),
and the steady-state model output is obtained across this range (Figure 6-5).
Results from the sensitivity analysis yielded several intriguing observations. Under normal
conditions, body weight is most prominently affected by the parameters that control food intake
(k4) and caloric density in the diet (pfood). This implies that normal variability in dietary intake
has more pronounced effects on body weight than variability in other factors such as leptin
transport rates or energy expenditure.
Note also that despite the lack of an explicit set-point, body weight is maintained within a narrow
range, such that even with a diet with very high caloric density, body weight is still relatively
low (-35g, vs. >50g in experimental C57B1/6J mice155). This indicates that change in input (e.g.
in dietary caloric content) alone is not sufficient for the development of obesity in the model as
currently constructed, with parameters derived using baseline conditions. More severe cases of
obesity can only develop if modifications are made to one or more of the model parameters.
Table 6-7. Range of values used for sensitivity analysis.
Parameter Range Justification
kl 1.25 - 2.7 Range given by Banks et al 21 for different regions
k2 15.6 - 31 of the brain
k3  ±1/3 *
k4 4.5 - 8.05 Range of literature data, as listed in Table 6-1
k 1/3 *
k6 206.4 - 283.2 Range of literature data, as listed in
Table 6-4
k7 1/3 *
k8  ±1/3 *
Rm  ±1/3 *
GFR 252 - 316.8 Values reported in119,120
RenClearance n/a +
Pfood 3.2 - 5.25 Low end = chow diet, high end = 60% high fat diet
* Literature values not available for these parameters, the range is estimated to be ±1/3 of the corresponding value as
listed in Table 1 in the main text. This estimation is based on the range of the other parameters k1,k2,k4, and k6,
where there is approximately 2x difference between the minimum and maximum values.
+ In this model changes in RenClearance is equivalent to changes in GFR (see equation 1), therefore sensitivity
analysis is not repeated for RenClearance.
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Figure 6-5. Sensitivity of the settling point model towards variations in individual parameters (kl - ks, Rsyn, GFR,
and Pfood). The specific model parameter being varied is stated in the x-axis of each graph. Parameters are varied
from across its physiological range (Table 6-7). Note that "physiological range" represents the variability of each
parameter in healthy animals under standard experimental conditions. Pathological states such as low GFR due to
renal failure, or special manipulations such as dietary dilution or exposure to taxing metabolic environments (e.g.
prolonged cold temperature) are not represented in this analysis. In this model, changes in RenClearance are
equivalent to changes in GFR (see equation 1), therefore sensitivity analysis was not repeated for RenClearance.
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Simulation of leptin resistance
Thus far we have assumed that the leptin transport and dose response functions are static, i.e.
blood-to-brain leptin transport, food intake and energy expenditure are constants at any given
leptin concentration. However, leptin resistance (decreased sensitivity towards leptin) is a
hallmark of diet-induced obesity. Transport of leptin across the blood-brain barrier is reduced in
the obese (peripheral leptin resistance)' 56' 157. There is also evidence that sensitivity to leptin in
CNS regulatory centers is decreased by obesity (central leptin resistance) - leptin affects food
intake and energy expenditure through STAT3 signaling, and obesity causes hypothalamic
STAT3 activation to become less responsive to leptin158 . Recent reports have also demonstrated
that the neural circuits regulating energy balance are surprisingly flexible even in adulthood 159'
160. Given the key role of leptin resistance in obesity, an individual's susceptibility towards leptin
resistance is likely to affect that person's propensity to becoming obese.
In our model, peripheral leptin resistance can be simulated by changing the parameters that
control blood-to-brain transport of leptin (kl, k2, k3), while central leptin resistance can be
simulated by changing the parameters that govern the leptin dose response curves for food intake
and energy expenditure (k4, k5, k7, ks). There is very little quantitative experimental data
available on how leptin resistance develops, or how it relates to existing leptin levels. We have
arbitrarily chosen to simulate peripheral leptin resistance by increasing k2 at high leptin
concentrations, according to the following ad hoc equation:
k 2 = k2, 0 + k 9 (Lep plasma - klo)X heaviside (Lep plasma - k1o) [Equation 8]
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Where k2,0 is the original k2 used in equation 2. klo is the level of plasma leptin at which
peripheral leptin resistance begins to develop. k9 is a dimensionless factor that scales the
increment in k2 with increasing plasma leptin. The last term is the Heaviside function that causes
k2 to be constantly equal to k2,0 at plasma leptin levels below k1o. Equation 10 simulates leptin
resistance by increasing k2 linearly when plasma leptin levels exceed klo, and assuming that this
mode of leptin resistance is fully reversible (Figure 6-6A,B).
We then chose values for k9 and klo empirically to simulate mice with different susceptibilities
towards leptin resistance. The threshold plasma leptin concentration (klo) which leptin resistance
begins to develop was assumed to be 10 ng/ml (recall that for our model the baseline steady state
plasma leptin concentration was 4.6 ng/ml). When k9 = 4, the model was resistant to diet-induced
obesity, and model outputs were consistent with data from obesity-resistant A/J mice (Figure
6-6C). When k9 was increased to 9 (in effect increasing the prominence of leptin resistance), the
model became susceptible to diet-induced obesity, and model outputs were consistent with data
from C57B1/6 mice (Figure 6-6D).
Another interesting observation came from this simulation of leptin resistance. In Figure 6-6D,
the difference between mice fed low fat diet for 4 months then high fat diet for 4 months (L4H4)
and the mice fed high fat diet for 8 months (H8) was due to kinetics - the L4H4 group had not
reached steady state at the last time point, and if the simulation of the L4H4 group were
continued on the high fat diet, eventually their body weight would reach a similar steady state
value as the H8 group. However, different combinations of k9 and klo could give rise to multiple
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steady states under identical environmental conditions (Figure 6-6E,F). Implications of this
phenomenon will be discussed below.
It should also be noted that in this model changes in the amount of leptin reaching the brain are
functionally equivalent to changes in the sensitivity of the CNS regulatory centers towards brain
leptin concentration, therefore LepBrain in Figure 6-6 can also be interpreted as the degree of
activation of the leptin pathway in the brain. This analysis can in fact be further extended to other
physiological factors that alter the leptin dose-response curves for food intake and energy
expenditure (e.g. changes in leptin transport/sensitivity caused by other neuroendocrine signals).
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Figure 6-6. Simulation of peripheral leptin resistance. (A) Modification of k2 according to Equation 10. k2 increases
at plasma leptin concentrations larger than the threshold level set by kl0o. k2,0 = baseline value of k2. The rate of
increase of k2 is determined by k9. (B) Blood-to-brain transport of leptin is decreased by increasing values of k2.
Each curve represents the relationship between plasma and brain leptin concentrations at one particular value of k2.
(C,D) Simulation of mice with different susceptibility towards leptin resistance, compared to experimental data from
Parekh et alss'55. Mice were given 4 different diet regiments over 8 months: low fat diet all 8 months (L8), high fat
diet for 4 months then low fat diet for 4 months (H4L4), low fat diet for 4 months then high fat diet for 4 months
(L4H4), or high fat diet for 8 months (H8). Dietary caloric content as reported by Parekh et al. Crosses and error
bars represent data reported by Parekh et al., while grey bars represent simulation results. (C) When the value of k9
is small, the simulated animal is consistent with mouse strains such as A/J that are resistant to diet-induced obesity.
(D) When the value of k is large, the simulated animal is consistent with mouse strains such as C57B6J that are
susceptible to diet-induced obesity. (E) Multiple steady states are possible when model parameters are permissible.
The values of k and klo in Equation 10 were set to 7 and 9, respectively, then the simulation was repeated with low
fat diet for 4 months, high fat diet for 4 months, then returned to low fat diet for 8 months. Even though all other
external variables, including the diet, were identical, the steady state body weights (arrows) were different before
and after exposure to the high fat diet. (F) Energy intake (solid line) and expenditure (dashed line) are plotted as
functions of plasma leptin concentration. Steady state occurs when energy intake equals expenditure (i.e. when the
two curves intersect each other). With model parameters used in (E) and a low fat diet, there are two possible stable
steady states (black arrows), and a third steady state that is unstable (white arrow). If acute fluctuations (such as a
temporary therapeutic intervention or change in diet) in system inputs lead to leptin levels on the left of the point
denoted by the white arrow, the system will eventually settle on the lower steady state (arrow 1). When fluctuations
lead to leptin levels on the right of this white arrow, the system will settle on the higher steady state (arrow 2)
instead.
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Set-point model
Simulation results using the set-point model at base-line (leptin pathway intact, normal chow
diet), as well as with disrupted leptin pathway, were similar to experimental data, and
comparable to results from the settling point model (Figure 6-7A). This is expected since we
have used steady-state results from the settling point model to define both the set-point and the
bias signals of the set-point model, while data from leptin knockouts were used to define the
upper and lower bounds for food intake and energy expenditure.
Response to dietary changes
To evaluate the response of the set-point model to changes in dietary caloric content, we repeated
the simulations with varying dietary caloric contents. When dietary caloric content was either
increased or decreased by 50%, there was a transient change in body weight and leptin levels, but
eventually all these parameters returned to the set-point, despite the persistent change in dietary
caloric content (Figure 6-7B). This result highlights one of the fundamental differences between
the settling point and set-point models: whereas a persistent change in input would cause a
corresponding shift in steady state output in the settling point model, in the set-point model such
a change would eventually be compensated for, upon which the controlled parameter would
return to the set-point.
This simulation also illustrates an important fact: diet-induced obesity is incompatible with any
set-point regulatory system, such as our set-point model, that is capable of returning the system
to the set-point. This is because the controlling actions in such systems are exerted as long as
there is a difference between the measured parameter and the set-point, and so the system always
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returns to the set-point eventually, regardless of variations in extrinsic factors such as dietary
caloric content.
In part to circumvent this limitation, proponents of the set-point theory have suggested that
perhaps the set-point is mobile, and that an increase in the set-point could explain the
development of obesity' 10. Since the mechanism by which the set-point could be altered has
never been specified, here we will briefly discuss two possible alternatives by which the set-
point could change in response to existing leptin concentration.
One suggestion is that perhaps the set-point can be permanently increased (e.g. in obese
individuals), but can rarely (if ever) be decreased' 10. The difficulty in lowering the set-point
would then contribute to the difficulty in losing weight once it is gained. This mode of set-point
change could be simulated by a set-point that changes according to the absolute leptin
concentration. Since the leptin concentration is always non-negative, this set-point can never
decrease. However, a set-point that is permanently increased implies that animals with diet-
induced obesity would retain their obese body weights even after returning to a standard diet.
This scenario would be analogous to the results shown in Figure 6-7B, but with a higher body
weight set point, which is contrary to results from animal studies showing that diet-induced
obesity is reversible when dietary caloric content is returned to normal 1', so a permanently
increased set-point change is not compatible with experimental data in rodents.
Another possible mechanism by which the set-point could vary is by changing the set-point in
response to the error signal. This would allow the set-point to change reversibly. The first reason
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this mode of set-point change is unlikely concerns leptin knockouts. Because leptin
concentration is constantly zero in leptin knockouts, a set-point that changes in proportion to the
error signal would eventually result in a set-point of zero, at which point the leptin knockout
animals would eat and expend energy similar to wildtype animals (Figure 6-7C), which clearly
does not happen in experimental animals. This obstacle could be partially circumvented if there
were some sort of threshold below which the set-point would not fall. However, even if the leptin
knockout scenario was not a problem, this mode of set-point change still requires the overriding
of the control mechanisms working to return the system to the original set-point. In other words,
this mode of set-point mobility could only become effective if the ability to return the system to
its original set-point was lost, resulting in a system much more akin to our previous settling point
system than a set-point system (Figure 6-7D). This limitation also applies to any other model
parameters that change in responses to the error signal (e.g. the earlier simulation of leptin
resistance by varying k2 in response to plasma leptin concentration).
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Figure 6-7. Simulations for set-point model. (A) Body weight in simulated WT mice (solid line) compared to leptin
knockout mice (dotted line). Experimental data for body weights of leptin knockout mice (crosses) and WT
C57B16/J mice (circles) are the same as Error! Reference source not found.. Simulation outcomes for both leptin
knockout and WT mice are similar to experimental data, and comparable to the settling point model. (B) Adaptive
changes in response to altered energy intake. Normal diet was eaten during weeks 0-4, while diet energy density
50% above normal during weeks 4-12, and 50% below normal during weeks 12-20. In both cases, compensatory
changes in food intake and energy expenditure combined to return body weight to the set-point (body weight at
which brain leptin concentration = 0.34 ng/g). (C, D) Set-point system with a set-point that changes in proportion to
the error signal, described mathematically by the equation: d(SeP a (Lep - SetPt ), where = a constant. With
this definition of a set-point, the set point reversibly adapts to existing leptin levels. (C) With this changeable set-
point, body weight in simulated wildtype mice (solid line) is still similar to experimental data (circles). However, in
simulated leptin knockout mice (dotted line) the set-point is continuously lowered so that body weight in these
similated mice was much lower than experimental data (crosses). (D) In wildtype mice with an adaptable set-point,
the system behaves much more similar to a settling point system than a set-point system (normal diet for weeks 0-10,
diet energy density 50% above normal for weeks 10-40, 50% below normal for weeks 40-70).diet energy density 50% above normal for weeks 10-40, 50% below normal for weeks 40-70).
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For the reasons listed above, even a set-point that is changeable (in response to leptin levels)
cannot adequately account for diet-induced obesity. Given that our previous simulation, using a
simple steady state system with no set-point, was able to reproduce experimental data of diet-
induced obesity with reasonable fidelity, we conclude that body weight regulation in
environments of ample dietary energy availability and the development of diet-induced obesity
are more consistent with our settling point model than one governed by set-point controllers.
Combination model
While our settling point model is sufficient to simulate the development of diet-induced obesity,
there is divergent experimental data when dietary caloric content is reduced below normal. Some
animals compensate by increasing the mass of food consumed, and are able to maintain their
body weights even at drastically reduced dietary caloric contents, while others are unable to
compensate at all145-147. In general, carnivores (e.g. dogs and cats) and herbivores (e.g.
oppossums and rabbits) are less able to compensate for reduced dietary caloric content, while
omnivores (e.g. mice, rats and humans) seem to be more effective at sensing and compensating
for fluctuations in dietary caloric content, although there are conflicting reports even in rodent
and human data. It has been suggested that the ability to appropriately adjust for dietary caloric
content may be more important in omnivores due to the wide variety of food they consume,
whereas this ability may not be necessary in herbivores and carnivores since they have relatively
constant diets in natural settings146
The ability to maintain a constant body weight even in the face of reduced dietary caloric density
is more compatible with the set-point model than the settling point model, since the latter could
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never completely compensate for changes in dietary caloric density. In equations 8 and 9, the
integral terms are responsible for the ability to completely eliminate even small errors. Thus in
animals that are able to completely compensate for reductions in dietary caloric content, food
intake and energy expenditure may be more accurately described by combining aspects of both
the set-point and settling point models, as follows:
FoodIntake
kj 1 LepBrain +a 2 (Lep thresh - Lep Brin (t))dt x Heaviside (Lep thresh - Lep rain ())
k5 + Lep Brain
=-BM x k 1 + k LP + a 4 (Lep thresh - Lep Brain (t))dt x Heaviside (Lep thresh - Lep Brain 
Where Lepthresh is the threshold leptin level below which the integral control actions become
active. Again, both food intake and energy output are bounded by maximum and minimum
values, as described during the derivation of equations 8 and 9. The integral and heaviside terms
in these equations allow leptin to function as a safeguard against starvation. At brain leptin
concentrations above the threshold, this "steady-state-plus-threshold" system still behaves like
the settling point model, where changes in input (e.g. dietary caloric content) would lead to new
steady states. However, if brain leptin concentration were to fall below the threshold, the control
mechanisms (described by the integral terms in the equations above) would become active,
preventing leptin concentration (and by extension, body weight) from falling below the threshold
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level (Figure 6-8) by increasing food consumption and reducing energy expenditure. The
magnitude of the parameters a2 and a4 would determine the strength of this starvation prevention
control action. Large values for a2 and a4 would confer robust compensatory abilities to
counteract decreases in dietary caloric density, while low (or even zero) values for a2 and a4
would lead to weak compensatory abilities.
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Figure 6-8. Different responses to altered energy intake by the different simulation models. (A-C) Normal diet was
eaten during weeks 0-5. Diet energy density was 50% above normal during weeks 5-15, and 50% below normal
during weeks 15-30. (A) Settling point model. This model partially compensates for the change in dietary energy,
but the compensation is not complete, leading to a new steady state for each diet. This model is compatible with
diet-induced obesity, and animals (such as cats and dogs) that do not compensate well against reduced dietary
energy density. (B) Set-point model. This model completely compensates for the change in dietary energy density,
so that body weight always returns to the set-point value. This model is incompatible with diet-induced obesity, but
the response to reduced dietary energy is consistent with animals (such as rats) that are able to maintain their body
weights despite reduced dietary energy density. (C) Steady-state-plus-threshold model. With increased dietary
energy density (weeks 5-15), this model behaves like the settling point model, allowing body weight to reach a new
steady state. But at reduced dietary energy density (weeks 15-30), the control action becomes active, returning body
weight to the threshold level (in this simulation the threshold brain leptin level was set to be 0.32 ng/g, close to the
baseline steady state level, so as to be consistent with previous data showing mice given diluted diets maintain their
body weights close to those of mice given standard chow ad libitum 145). This model allows the development of diet-
induced obesity, but also protects more vigorously against starvation. The x- and y-axes are kept constant for graphs
A-C for easy comparison. (D) Leptin resistance (as mathematically defined earlier) was included in the steady-state-
plus-threshold system. Normal diet was eaten during weeks 0-10. Diet energy density was 50% above normal
during weeks 10-30, and 50% below normal during weeks 30-40. The simulated animal developed diet-induced
obesity when dietary caloric density was increased, but was able to compensate for below-normal dietary caloric
density and prevent its body weight from falling below the threshold level.
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Discussion
A number of investigators have used mathematical modeling to study the regulation of energy
metabolism and body weight 61-164 . However, most of these previous models did not directly
address the feedback regulatory mechanisms that regulate food intake and energy expenditure.
This may be because most previous models were based on human experiments where food intake
was the primary experimental variable, and was determined by the investigator, rather than the
subject. Thus the effects of neuroendocrine signals (such as leptin) on feeding were overridden,
and therefore such data is not suitable for simulating the regulatory system that controls energy
homeostasis under normal, free-feeding conditions.
Here we have developed a mathematical model that explicitly simulates the effects of leptin on
energy balance, with parameters derived from published experimental data. Our model
reproduces key characteristics of the energy regulatory system - the model produces and defends
a stable body weight, the effects of leptin pathway disruption are consistent with experimental
results from leptin knockout mice, and varying degrees of susceptibility to leptin resistance
(specifically demonstrated for parameter k2) can result in substantial variations in susceptibility
towards diet induced obesity.
Our results showed that an explicit set-point is not required for a stable body weight that is
apparently defended against environmental perturbations, and that a settling point model is more
consistent with experimental data of diet-induced obesity. On the other hand, our model differs
from the prevailing "settling point" concept in that our model includes active regulatory
mechanisms (i.e. food intake and energy expenditure both respond to leptin levels), and that
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intrinsic factors, such as leptin sensitivity, are at least as important as external environmental
factors in the development of diet-induced obesity, as we illustrated in our sensitivity analysis
and simulation of leptin resistance. We further demonstrated that a hybrid model combining
aspects of both set-point and settling point models can more accurately represent animals that are
susceptible to diet-induced obesity, yet are still able to compensate for diminished dietary caloric
content. This "steady-state-plus-threshold" model is consistent with data showing that low levels
of leptin elicits potent anti-starvation responses, while high leptin levels are only partially
effective at limiting adiposity112' 165. Whether this threshold value could change in response to
leptin levels remains to be determined experimentally, but if this threshold value can be raised in
response to chronically high leptin levels, it could contribute to the difficulty in losing weight.
Our model predicts that different degrees of susceptibility towards peripheral leptin resistance
could account for differences in susceptibility towards diet-induced obesity. One way to test this
prediction is by quantifying the change in dose-response towards leptin under conditions of
chronic high central leptin levels, and comparing results between mouse strains with different
susceptibilities towards diet-induced obesity. Such a study would also be very beneficial towards
formulating a more rigorous mathematical description of the development of leptin resistance. In
addition, the kinetics for the development of leptin resistance is likely to be quite different than
those for energy homeostasis responses. A mathematical model that incorporates both of these
kinetic profiles would be very helpful in understanding how these long- and short-term responses
towards leptin interact to affect the overall system. Also of note, in the same simulation (depicted
in Figure 6-6C,D), the two strains of mice had very similar body weights on a low fat diet. Thus
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the propensity for diet-induced obesity in animals more susceptible to leptin resistance was not
manifested until exposure to a calorie-rich diet.
When leptin resistance was included in the simulation, multiple stable steady states were possible
(given permissible parameter values) under identical external conditions. Systems with multiple
steady states are quite common, and detailed explanations for these systems can be found in
textbooks on chemistry, thermodynamics or reaction engineering 66. In Figure 6-6F, the white
arrow marks the unstable steady state, which is also the point of division between the two stable
steady states. When transient changes lead to plasma leptin levels to the left of this white arrow,
the system will eventually settle at the lower steady state. However if plasma leptin levels were
to rise to the right of the white arrow, then the system will settle at the higher steady state. This
behavior reveals a potential mechanism contributing to the difficulty in maintaining weight loss
- once the system settles into the higher steady state, attempts to changed the body weight will
be opposed by the same mechanisms as depicted in Figure 6-4, and will have no long-term effect
unless they are strong enough to force the system back to the left of the white arrow (note that in
Figure 6-6E, after the animal was exposed to high fat diet for 4 months then returned to low fat
diet, the new steady state body weight was substantially higher than the previous steady state on
low fat diet). Identification of conditions that give rise to multiple steady states could enable the
design of therapeutic interventions to "push" an individual's body weight back to a lower,
healthy steady state that would persist even after the interventions are withdrawn, as well as the
development of therapies that could lower the barrier for transition from the higher to the lower
steady state (analogous to the role of catalysts and enzymes in chemical reactions). This finding
from our model points to the need for more experimental data to validate whether multiple
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steady states exist in energy metabolism, and if they do to determine the specific conditions
giving rise to the different states.
It should also be noted that while the leptin resistance function we used in this model was fully
reversible, it is quite possible that obesity could bring about changes in an individual's
physiology that are only partially reversible, or even completely non-reversible (the decision to
model leptin resistance as a reversible function was arbitrary -there is currently not enough
experimental data to definitively describe the development or "behavior" of leptin resistance). In
such cases the permanently altered model parameters could give rise to differences in a formerly-
obese individual's metabolic profile that would persist even after the individual returns to a
lower body weight.
The validity of outcomes from any mathematical model is critically dependent on the validity of
the model's underlying assumptions. The major assumptions made to formulate our current
model have been listed in the Supplementary Materials. The following are some future avenues
of investigation identified by our model that would enable the relaxation of some of the model
assumptions, paving the way for more comprehensive models:
1. More quantitative experimental data on the development of leptin resistance is required to
formulate models of leptin resistance based on molecular mechanisms (an ad hoc
equation was used in our model due to lack of data). Given the central role of leptin
resistance in obesity, such data would also likely yield beneficial insights regarding the
treatment of obese patients.
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2. Data on how changes in energy balance (including changes in quantity and mode of
energy intake/output, e.g. starvation vs. physical activity) lead to changes in fat and fat-
free mass over a wide range of experimental conditions (especially during prolonged
starvation or muscle-building exercise) would allow the modeling of how energy intake
and expenditure affect either the total mass or metabolic profile of fat-free mass.
3. Although leptin is a principal determinant of energy metabolism, it is not the only
important signal. Other signals such as insulin and short-term satiety signals have not
been explicitly modeled in our simulations. Inclusion of these signals would give a much
more comprehensive model. Because of the domineering effects of leptin, experiments
must be cautiously designed to isolate the effects of other signals from leptin's
confounding effects.
4. The current model only addresses intermediate time scales (days-weeks). Events that
occur outside these time intervals were not explicitly modeled due to the paucity of
experimental data. More data in these areas would enable the formulation of more
powerful models: a model that is accurate to shorter time scales would allow for the
evaluation of important factors such as meal patterns, intestinal motility and diurnal
variation in hormone and physical activity levels; whereas inclusion of long-term effects
would enable the assessment of changes to the metabolic system caused by chronic
obesity and aging.
Our present model was constructed for mice. Studies in mice have been crucial in forming our
understanding of human obesity - most of the key molecular pathways regulating energy
metabolism were originally identified and characterized in mice, and the varying degrees of
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susceptibility towards diet-induced obesity among different mouse strains is a valuable tool for
studying polygenic obesity (which is the norm in humans). However, there are also fundamental
differences between human and mouse metabolism. For example, thermogenesis in brown fat
represents a significant source of energy expenditure in mice, whereas human adults have very
little brown fat. Therefore the same caution that is taken when results from animal experiments
are applied to our understanding of human diseases must be taken also with lessons drawn from
mathematical models (such as ours) that are based on animal data. Currently the difficulty in
obtaining reliable, long-term metabolic data for humans in their natural settings presents a major
hindrance against developing a similar model for humans. Ethical concerns have also
appropriately excluded human data that require invasive collection techniques. Until
technological advances make such data available, the best option may be to develop more
sophisticated and accurate models based on experimental animals, and judiciously apply new
understandings gained from these models to the human disease. In the meantime, our current
model can serve as a unified theoretical framework to interpret existing data regarding body
weight regulation, and to identify experiments that need to be done to resolve outstanding
controversies.
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